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Dendritic spines are the predominant site of glutamatergic inputs throughout the brain. 
Regulation of spines is therefore critical for refining cortical networks. This research sought to 
define mechanisms for determining spine fate during developmental synapse remodeling. The 
central hypothesis is that NrCAM requires intracellular interactions within the spine to promote 
Semaphorin3F receptor clustering and spine retraction, through binding to the actin adaptor 
AnkB and microtubule binding protein DCLK1. I have delineated intracellular binding partners 
of NrCAM in synapse-enriched cellular fractions. I made a mutation in NrCAM that disrupts 
binding to AnkB and DCLK1 and perturbs Sema3F holoreceptor functioning. I demonstrated 
that chemical disruption of microtubules affects spine morphology and response to Sema3F. 
Finally, I have shown in vivo mutations affecting AnkB result in altered spine densities. The 
findings provide insight toward understanding the molecular mechanisms of dendritic spine 
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CHAPTER ONE: INTRACELLULAR INTERACTIONS OF NrCAM REQUIRED FOR 




The refinement of neuronal connectivity during adolescence is an important milestone of 
human development. For information to be efficiently transmitted locally within a region and 
distally across the brain, a finely tuned cooperation between excitatory and inhibitory signals (E/I 
balance) must be acquired. To achieve this, cortical development in the adolescent brain 
undergoes two distinct phases: an initial overabundance of synapses is formed, composed 
primarily of excitatory inputs onto dendritic spines, followed by a “remodeling” period of 
pruning spines to refine connectivity and establish E/I balance.1–4 This is particularly important 
within the medial frontal cortex (MFC), where essential circuits regulate social behavior, 
working memory, and cognition relevant to neurodevelopmental disease. Dysregulation of 
synaptic connectivity manifests into psychiatric disorders, including autism spectrum disorder 
(ASD), bipolar disorder, and schizophrenia; yet few of the molecular mechanisms underlying 
synaptic refinement have been identified. A leading hypothesis in the field is that defective spine 
pruning results in too great of a spine density within the cortex, causing the hyperexcitability 
phenotype seen in ASD and other neurodevelopmental disorders. Conversely, overactive spine 
elimination results in too few spines, a common phenotype seen in schizophrenia.5 Therefore, 
determining the molecular mechanisms by which dendritic spines are fated for removal or 
maturation would not only benefit our understanding of the development of the mammalian 
nervous system, but also provide vital insights into the pathogenesis of
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psychiatric diseases which may be due to aberrant refinement of spines.  
One mechanism by which synaptic refinement is known to occur is through repellent 
signaling by the Semaphorin family of proteins.6 Semaphorins participate in both local and distal 
signaling, through their expression as transmembrane isoforms, or by their secretion into the 
extracellular space (Class 3 Semas).7 Expression of Semaphorin receptor molecules on the 
surface of a dendritic spine dictates whether the spine is resistant or destined for elimination. The 
Maness lab has identified an obligate role for the cell adhesion molecule, Neuron-glial related 
cell adhesion molecule (NrCAM), within the Semaphorin3F (Sema3F) holoreceptor complex.8 
This heterotrimeric receptor complex consists of NrCAM, Neuropilin 2 (Npn2), and Plexin A3 
(PlexA3), which co-cluster upon exposure to Sema3F, causing signal transduction, spine 
retraction, and elimination of the synapse. Knockout mice lacking NrCAM, Npn2, PlexA3, or 
Sema3F display excess spines and excitatory synapses on apical but not basal dendrites, and 
exhibit cortical hyperexcitability.6,8 Apical dendrites are known to differ from basal dendrites in 
functional connectivity and integration of inputs.6,8  
NrCAM is a transmembrane protein with a cytoplasmic domain containing motifs that 
link to the cytoskeleton. The cytoskeleton within the dendritic spine exhibits a unique feature of 
being composed almost entirely of filamentous actin (F-actin), in contrast to the dendritic shaft, 
which relies on microtubules for branching and structural rigidity.9,10,11 L1, a close relative of 
NrCAM, binds the actin adaptor proteins Ankyrin B (AnkB) and Ankyrin G (AnkG) important 
for axon guidance. This interaction is shown to be dependent on tyrosine dephosphorylation in 
the “FIGQY” motif of the L1 cytoplasmic tail.12 Phosphorylation of the tyrosine residue in 
FIGQY of L1 by EphB2 disrupts the ankyrin interaction. Analysis of microexons in autistic 
patients revealed a misregulated protein-interaction network consisting of AnkB and NrCAM,13 
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and 12 human genetic reports identify AnkB (Ank2) as a high confidence autism risk factor in the 
SFARI gene database.14–17  However, little is known about the role for neuronal AnkB during 
postnatal brain development because germline knockout of AnkB is 90% lethal by postnatal day 
P2, and 100% lethal by P21.18 Thus, it is of critical importance to utilize a novel approach to 
identify a role for AnkB in dendritic spine development. To do this, I have generated the first 
conditional, inducible AnkB knockout mouse with an EGFP reporter (Nex1Cre-ERT2: AnkBloxP: 
EGFPloxP), in which AnkB can be deleted in cortical pyramidal neurons at specific time points 
throughout development. Using this tool, I have identified an in vivo dendritic spine phenotype 
due to AnkB deletion at postnatal and adult stages, revealing an importance for this protein in 
refining synaptic connectivity.  
An important goal is to define at the molecular level the binding partners of the NrCAM 
cytoplasmic tail, that contribute to the functional Sema3F holoreceptor complex. Previous work 
has shown that when the consensus FIGQY motif is phosphorylated on tyrosine, the L1CAM 
family member Neurofascin dissociates from Ankyrin12, and binds the lisencephaly protein 
Doublecortin (DCX).19 NrCAM was shown not to bind DCX,19 however, I show here that 
NrCAM binds a DCX homolog, Doublecortin-like Kinase 1 (DCLK1). DCLK1 is a microtubule-
binding protein with serine/threonine kinase activity, important for microtubule bundling and 
linkage to F-actin.20,21 Like NrCAM, DCLK1 has been shown to constrain spine density and 
regulate spine morphology (an indication of mature vs. immature spines).22 Thus, I hypothesized 
that direct interactions of NrCAM with the dendritic cytoskeleton through AnkB and DCLK1 is 
required for Sema3F-holoreceptor functioning, and that tyrosine phosphorylation of NrCAM 
FIGQY acts as a molecular switch for binding of AnkB to regulate sensitivity to Sema3F-
induced spine retraction.  
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 It is of crucial significance to improve our knowledge of how the developing brain 
determines which connections to keep and which ones to eliminate, to produce a healthy 
functioning central nervous system. Because glutamatergic inputs onto dendritic spines represent 
>90% of the connections in the brain, the regulation of spine fate presents the most likely avenue 
for understanding this process. The Sema3F-mediated elimination signals outlined here provide a 
robust mechanism for signaling for spine retraction. Other emerging regulators of spine 
elimination involve astrocyte-mediated engulfment of spines,23 microglial phagocytosis,24,25 and 
autophagic recycling through mTOR signaling.26,27 The experiments performed in this project are 
expected to contribute to our understanding of the developmental spine refinement period. The 
data shown can likely be extended towards understanding how other repellent ligands 





MATERIALS AND METHODS 
Mice 
Wild type (WT) mice were on a C57Bl/6 background from Jackson Laboratories. 
NrCAM-null (gift from Dr. Martin Grumet), were originally on a mixed background of 
129S6/EvSvTac and Swiss Webster, but were subsequently bred into a C57Bl/6 background. 
L1Y1229H mutant mice are on a C57Bl/6 background. Because the L1 gene is on the X 
chromosome, heterozygous females were crossed with C57Bl/6 WT males to obtain WT and 
hemizygous male mutants for analyses (homozygous mutation in females resulted in embryonic 
lethality). Ankyrin B floxed mice28 were crossed to the NexCre-ERT2 line29 to induce 
recombination in postmitotic, postmigratory pyramidal neurons upon induction by treatment with 
tamoxifen, as described.29 Induction of CreERT2 in a sparse population of cells was performed 
through daily intraperitoneal administration of 4-hydroxy-tamoxifen from P10 to P13, and mice 
were analyzed at P28 or P50. The Rosa-CAG-EGFP (RCE, gift from Gordon Fischell) reporter 
mouse line was crossed to the NexCRE-ERT2 mice prior to breeding with Ankyrin B floxed 
mice. It contains a loxP-stop-LoxP EGFP allele for specific labeling of Cre-induced cells. 
Immunoreagents and chemicals 
Monoclonal antibodies used were directed against NrCAM (Abcam, ab24344), ankyrin B 
(Thermo Fisher, 33-3700), DCLK1 (Abcam, ab31704), spinophilin (Millipore, 06-852) phospho-
FIGQY (Bethel Laboratories, made on-demand). Polyclonal antibodies were: Npn-2 (R&D 
Systems, AF567), PlexA3 (Abcam, ab41564), EGFP (Abcam, ab13970). Normal rabbit IgG was 
obtained from Jackson Immunoresearch. Horseradish peroxidase, Alexafluor488, Alexafluor555, 
and Alexafluor647-conjugated secondary antibodies were obtained from Jackson 
Immunoresearch. For western blotting all antibodies were diluted in 5% milk/TBST. Primary 
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antibodies were used at a 1:1000 dilution from stock, HRP anti-mouse 1:5000, and HRP anti-
rabbit 1:10,000. For immunostaining, primary antibodies were used at 1:500 dilution in 5% 
donkey serum/PBS, and AlexaFluor 488, 555, and 647 secondary antibodies were used at 1:500 
dilution in PBS. Fc fragment from human IgG was from Abcam, and Sema3F-Fc fusion protein 
was from R&D systems. Microtubule perturbing compounds taxol and nocodazole were 
purchased from Sigma Aldrich. 4-hydroxy-tamoxifen for induction of NexCre-ERT2 was 
purchased in freebase form from Sigma (T5648) and dissolved in sunflower oil (Sigma, S5007). 
HEK293T cell culture and transient transfection 
HEK293T cells were grown in DMEM supplemented with gentamicin/kanamycin 
(Sigma) and 10% FBS (Gibco) in a humidified incubator with 5% CO2. On the day before 
transfections, cells were seeded at 1x106 cells per 100mm dish. Plasmids containing WT or 
mutant NrCAM were cotransfected with either Ankyrin B or DCLK1 at a 2:1 molar ratio with 
Lipofectamine 2000 (ThermoFisher, 11668) following manufacturer protocol. Media was 
changed on the day following transfection, and cells harvested 48 h later in RIPA (20 mM Tris, 
pH 7.0, 0.15 M NaCl, 5mM EDTA, 1 mM EGTA, 1% NP-40, 1% deoxycholate, 0.1% SDS, 200 
µM Na3VO4, 10 mM NaF, 1x Protease Inhibitor Cocktail (Sigma)) or Triton (20 mM Tris, pH 
7.0, 150mM NaCl, 5 mM EDTA, 1 mM EGTA, 1% TritonX100, 10 mM NaF, 1x Protease 
Inhibitor Cocktail (Sigma)). Protein concentrations were determined using BCA. 
Synaptoneurosome Preparation 
Synaptoneurosomes were isolated as in Villasana et al.30 Adolescent aged wild type mice 
were anesthetized, decapitated, and the cortex isolated (n = 4 brains per SN prep) then dounce 
homogenized in synaptoneurosome buffer containing additives (10 mM HEPES, 1 mM EDTA, 2 
mM EGTA, 10 mM NaF, 1x Protease Inhibitor Cocktail (Sigma)) for 20 strokes on ice. 
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Homogenate was briefly sonicated 6x for 10 seconds each with 60 seconds of rest on ice between 
each cycle, then filtered 3x through a 100 µm nylon filter followed by 1x through a 5 µm cell 
strainer. The final filtrate was centrifuged at 1000 x g for 10 minutes at 4 oC. The pellet was 
resuspended in 500 µL of TRITON lysis buffer containing additives, nutated on a rocker for 40 
minutes at 4 oC, then centrifuged at 16,000 x g on a table top centrifuge for 10 minutes at 4 oC. 
The supernatant was collected as a the synaptoneurosome fraction, protein concentration 
determined using BCA, and PSD95 enrichment verified through SDS-PAGE and western 
blotting. 
Immunoprecipitation 
Mouse forebrain lysates were extracted and dounce homogenized for 20 strokes in RIPA. 
Homogenate was incubated for 15 minutes on ice, then centrifuged at 16,000 x g for 10 minutes. 
The supernatant was retained and protein concentration determined through BCA. Forebrain 
lysates (1 mg) or HEK293T cell lysates (0.5 mg) were precleared for 30 minutes at 4 oC using 
Protein A/G Sepharose beads (ThermoFisher). Precleared lysates were incubated with 3 µg of 
NrCAM or nonimmune rabbit IgG antibodies for 2 h on ice. Fresh Protein A/G sepharose beads 
were added for an additional 30 min with nutation at 4 oC before washing with RIPA or 
TRITON. Beads were washed 4x, then immunoprecipitated proteins were released from the 
beads by boiling in SDS-PAGE sample buffer (125 mM Tris pH 6.8, 4% SDS, 20% glycerol, 
10% β-mercaptoethanol, 2 mM EDTA, 0.005% bromophenol blue). 
Cortical neuron culture 
Cortical neurons were prepared from brains of WT or NrCAM-null embryos (E15.5) and 
transfected with pCAGG-IRES-mEGFP (empty vector), pCAGG-IRES-NrCAM-EGFP (WT 
NrCAM), or pCAGG-IRES-FIGQH-EGFP (Y1231H mutant), as described.6,8 Media was 
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changed every 48-72 hours until DIV 14. At DIV 14, cultures were treated with DMSO (0.5%), 
Taxol (100 nM), or Nocodazole (7 µM) for 4 hours, or Sema3F-Fc and Fc control protein (3 nM) 
for 30 minutes. Cultures were fixed with 4% PFA for 20 min, permeablized with 0.3% 
TritonX100 for 30 min, blocked with 10% donkey serum for 1 h, and stained with primary 
antibodies (1:500) overnight. AlexaFluor488, 555, or 647 secondary antibodies (1:500) were 
incubated for 1h the next day. Images were captured on a LSM700 confocal microscope with 
20x/0.8 NA Plan Apo lens for whole neuron images, or a 40x/1.4 NA Plan Apo oil immersion 
lens with 2.5x optical zoom for dendritic spine images. Spines of labeled neurons were measured 
on dendrites of at least 10 neurons in each of four replicate cultures per condition. Mean spine 
densities ± SEM were determined for each condition and compared by two tailed t test (p < 
0.05). For co-localization analysis, EGFP was used to label neurons, and proteins of interest 
labeled with AF555 and AF647.31 ImageJ Coloc2 plugin was used to quantify colocalized pixels 
and represented by thresholded Mander’s coefficient and Pearson’s Coefficient, and means ± 
SEM compared by two tailed t test (p < 0.05). 
Spine density and Sholl analysis of Golgi-impregnated neurons  
Mice (P60) were anesthetized with isofluorane and brains were removed and processed 
for Golgi staining using the FD Rapid GolgiStain Kit (FD NeuroTechnologies, PK 401). Brains 
were embedded in Golgi solutions A & B for 3 weeks, then flash frozen in isopentane pre-chilled 
on dry ice. Frozen brains were cryostat sectioned (100 µm coronal) and mounted on gelatin-
coated microscope slides for histochemical staining according to manufacturer protocol. Golgi-
labeled neurons were analyzed in coronal sections of mouse brain using an Olympus BX-61 
microscope with z-stack capabilities, and images captured with a 20x objective for Sholl analysis 
and 63x objective for spine analysis. Spine density and dendritic branching were quantified using 
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Neurolucida software (MBF Bioscience). For apical dendrites, spines were scored along the 
primary segment 100-150 µm distal to the soma. For basal dendrites, spines were scored along 
35-50 µm segments on 3-5 secondary branches. Mean spine number per 10 microns of dendrite 
(density) was calculated. For Sholl analysis, the center of concentric circles was defined as the 
center of the cell body, and then dendritic arbors traced manually, with a starting radius of 10 µm 






NrCAM interactions at the synapse and dependence on Tyr1231 
 
To evaluate a role for an interaction between the cytoplasmic tail of NrCAM with the 
cytoskeleton of dendritic spines, a series of co-immunoprecipitation binding assays were 
performed in lysates collected from synaptoneurosome fractions of wild type brain tissue, and 
whole protein lysates from HEK293T cells transfected with cDNAs for proteins of interest. 
NrCAM was found to immunoprecipitate with both AnkB and DCLK1 from synaptoneurosomes 
(Fig 1A), which are fractionated pre- and post-synapse compartments collected from whole 
mouse cortex. DCLK1-interacting protein Spinophilin, and the guanine nucleotide exchange 
factor Tiam1 were also shown to immunoprecipitate with NrCAM (Fig 1A). High magnification 
confocal imaging of wild type cortical neurons labeled with EGFP and immunostained for 
NrCAM and AnkB reveal co-localization of these two proteins within the dendritic spine (Fig 
1B). To determine whether these proteins directly bind NrCAM or indirectly associate through a 
complex, I expressed each protein in isolation with NrCAM using Lipofectamine2000 co-
transfection of cDNAs into HEK293T cells. Interestingly, only AnkB and DCLK1 were shown 
to bind NrCAM in this system (Fig 1B,C). Co-transfection of NrCAM with Tiam1 cDNA did not 
yield any Tiam1 pulled down when expressed in isolation (Data not shown). Furthermore, 
coexpression of AnkB with DCLK1 in HEK293T cells revealed no direct binding, suggesting 
these proteins bind to NrCAM independently of each other (Fig 1D).  
 To further explore the binding of AnkB and DCLK1 to NrCAM, I generated a tyrosine-
1231 to histidine point mutation in the putative AnkB binding site on the cytoplasmic tail of 
NrCAM, termed Y1231H, and co-expressed this cDNA in HEK293T cells with AnkB or 




Figure 1. Intracellular interactions of NrCAM at the synapse. (A) Synaptic subcellular fractions, 
“synaptoneurosomes,” were isolated from p28 mouse forebrain, NrCAM co-immunoprecipitated, and 
immunoblotted for intracellular binding partners. (B) HEK293T cells transfected with cDNAs for AnkB220-HA +/- 
WT NrCAM or Y1231H mutant show reduced binding in Y1231H. AnkB220-HA transfection in the absence of 
NrCAM was treated as negative control. (C) HEK293T cells transfected with DCLK1 +/- WT NrCAM or Y1231H 
mutant and co-immunoprecipitated for NrCAM. (D) HEK293T cells transfected with AnkB220-HA and DCLK1 
cDNAs, and co-immunoprecipitated for AnkB demonstrate no binding interaction. (E) High resolution confocal 
imaging of wild type neuron labeled with EGFP and immunostained for AnkB (red) and NrCAM (blue) show 
colocalized pixels within the head of dendritic spines (white arrow). Scale bar = 3 µm. 
 
NrCAM/AnkB interaction was significantly reduced (Figure 1B). This mutation is homologous 
to the L1 syndrome Y1229H mutation in the L1 cell adhesion molecule, a close relative of 
NrCAM.  
Y1231H mutation in cytoskeletal binding site disrupts Sema3F-induced spine retraction 
and Npn2/PlexA3 clustering 
 
Because NrCAM has been previously identified as a critical mediator for the repellent 
function of the secreted Semaphorin3F ligand,8 I wanted to explore whether the loss of binding 
to the AnkB and DCLK1 cytoskeletal interactors would affect the ability of Sema3F to initiate 
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spine retraction. To do this, I designed a rescue experiment using Lipofectamine2000 
transfection of NrCAM cDNAs into cortical neuron cultures generated from NrCAM-null mice, 
and then treated these neurons with recombinant Sema3F-Fc or Fc control for 30 minutes. These 
neurons were labeled by an EGFP reporter on the cDNA vector to identify which neurons 
received the rescue construct (Fig 2A). Spine density was assessed on apical dendrites of 
pyramidal neurons, 100-150 µm from the soma, because our lab previously identified that 
Sema3F spine retraction signaling only effects apical dendrites and not basal. As a control, 
empty pCAGGS-IRES-EGFP vector was transfected and shown to have no effect on rescuing the 
spine retraction phenotype typical of Sema3F-Fc treatment, while transfection of WT NrCAM 
plasmid resulted a 33% reduction in mean spine density, represented as spines per 10 µm of 
dendrite. Rescue with the Y1231H NrCAM was unable to rescue the Sema3F spine retraction 
phenotype (Fig 2A,B). 
 Our lab has previously shown that treatment of neuron cultures from wild type mice 
causes clustering of Npn2 and PlexA3, subunits of the Sema3F holoreceptor complex, as 
indicated by their increased co-localization in immunostaining along dendrites.31 I used this 
model to explore the putative mechanism for the loss of spine retraction in NrCAM-null neurons 
rescued with Y1231H. Neurons were cultured from NrCAM-null neurons, transfected with WT 
or Y1231H pCAGGS-IRES-EGFP plasmids, and surface stained for extracellular Npn2 and 
PlexA3 (Fig 2C). Confocal imaging and ImageJ colocalization software were used for analysis. 
Baseline co-localization across all transfection conditions treated with recombinant Fc protein, 
demonstrated by a mean Pearson’s P value between 0.25-0.35 (Fig 2D) and mean thresholded 
Mander’s tM1 and tM2 coefficients from 0.40-0.55 (Fig 2E,F) were low. Following 30 min 




Figure 2. Y1231H mutation disrupts Sema3F holoreceptor functioning. NrCAM-null neurons were transfected with 
EGFP vector, WT NrCAM, or Y1231H mutant in pCAGG-IRES-mEGFP, treated with Fc or Sema3F-Fc for 30 
minutes on DIV14, immunostained for EGFP, and apical dendrites imaged confocally. (B) Quantification of mean 
spine density ± SEM on apical dendrites (n > 10 neurons per condition, t test, *P < 0.05). (C) Confocal images of 
apical dendrites of NrCAM-null neurons transfected as described in (A), treated with Fc or Sema3F-Fc for 30 
minutes, and stained for Npn2 (red) and PlexA3 (green). Merged images and heat maps of colocalization are shown. 
Scale bar = 5 µm. (D) Bar graph of Pearson’s R-total coefficient evaluating degree of colocalization and colocalized 
pixel intensity (n = 3 replicates, 10 neurons/replicate/condition, *P < 0.05). (E,F) Thresholded Mander’s coefficients 
demonstrating degree of pixel colocalization, in (E) Npn2 vs PlexA3, in (F) PlexA3 vs Npn2 (n = 3 replicates, 10 
neurons/replicate/condition, *P < 0.05). Open circles represent Fc-treated neurons, open squares represent Sema3F-
Fc treatment. 
 
pixels increased to 150% of baseline across all statistical measures for WT NrCAM rescue 
 
neurons compared to Fc controls, but no difference was seen for NrCAM-null and His1231- 
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expressing neurons (Figs 2D,E,F).  
Chemical disruption of microtubules significantly impairs dendritic spine health and 
functioning 
 
The requirement for Tyr1231 residue for binding of NrCAM and the microtubule-binding 
protein DCLK1, and the loss of Sema3F-induced spine retraction due to this mutation suggests a 
potential role for microtubules in the spine retraction mechanism. To pursue this hypothesis, I 
treated wild type cortical neuron cultures with the microtubule stabilizing compound Paclitaxel 
(10 nM, 4 hours) and the microtubule destabilizing compound Nocodazole (7 µM, 4 hours), and 
measured the efficacy of Sema3F-Fc treatment on spine density. Low magnification confocal 
imaging revealed an abundance of filopodial protrusions on nocodazole treated neurons (Fig 
3A), suggesting a requirement of microtubules in constraining spinogenesis. Confocal analysis of 
the dendritic spines of apical dendrites (Fig 3B) revealed a significant impairment of Sema3F-Fc 
induced spine retraction when microtubule function is disrupted, whereas 0.1% DMSO vehicle 
controls were unaffected (45% reduction in spine density for DMSO control, 13% reduction in 
paclitaxel treated neurons, and 3% reduction in nocodazole treated neurons, ± SEM). There was 
lowered baseline level of spine density in the Fc-treated control groups of 12% and 21% for 
paclitaxel and nocodazole treated groups, respectively.  
Dendritic spines in culture can be found in both their immature and mature states, based 
on morphological characteristics. An observation was made during confocal imaging that the 
nocodazole treated neurons displayed significantly more immature filopodial spines than 
controls. Further analysis of the ratio of immature to mature spines in each condition was 
conducted and revealed a 58% to 42% ratio of immature to mature dendritic spines in the Fc-
treated DMSO control neurons, however in the PAC and NOC-treated neurons there were 




Figure 3. Chemical disruption of microtubules impairs spine development and retraction. (A) Wild type neuron 
cultures were transfected with pCAGG-IRES-mEGFP vector, and treated with 100 nM paclitaxel or 7 µM 
nocodazole for 4 hours prior to treatment with 3 nM Fc or Sema3F-Fc. Whole neurons were imaged using confocal 
microscopy (20x objective, 0.8 NA) to assess cellular morphology. (B) High magnification images (40x obj, 1.4 
NA, 2.5x optical zoom) of apical dendrites from neurons described in A. (C, D) Quantification of dendritic spine 
density (mean spine density ± SEM, n = 3 replicates, 10 neurons/replicate/condition, t-test, *P < 0.05) and 
morphologies (mean ratios ± SEM, two-way ANOVA, *P < 0.05) 
 
88% to 12%, respectively (mean ratios ± SEM, two-way ANOVA). Across all treatment 
conditions, there was approximately a 6:1 ratio of immature:mature spines following 30 minute 
Sema3F-Fc treatment, demonstrating that mature spines are preferentially lost upon Sema3F 
holoreceptor activation. 
Y1229H mutation in L1 cell adhesion molecule affects spine density in vivo 
 
The Tyr to His mutation in the conserved cytoplasmic FIGQY binding site of L1-CAM 
family members has been identified as a risk factor for the human L1 syndrome 
neurodevelopmental disorder. Our lab previously identified a loss of binding between Ankyrins 
and L1 in a mouse model containing this mutation. To determine a molecular phenotype for the 




Figure 4. L1YH mutation increases spine density on apical dendrites but has no effect on dendritic branching. (A) 
Representative golgi-labeled pyramidal neurons in MFC of P60 adult mice. (B) Sholl analysis of dendrite 
arborization quantified in 10 µm increments from the cell soma, means ± SEM (3 mice, n = 10 neurons/mouse). (C) 
Representative Golgi-labeled apical dendrites from WT and L1YH P60 adult mice, scale bar = 5 µm). (D) 
Quantification of mean spine density ± SEM from golgi-labeled apical dendrites as shown in C (n = 3 
mice/genotype, 10 neurons/mouse, *P < 0.05) 
 
staining of mouse brains containing the Y1229H mutation in the L1 gene, a close family member  
of NrCAM. Coronal sections were taken from the medial frontal cortex (MFC) of L1YH mice 
sacrificed at postnatal day P60, when the remodeling of spine density during adolescence has 
been completed. Low magnification wide field light microscopy images (20x objective/0.5 NA, 
1 µM z-series sections) were captured to analyze whole-cell dendrite arborization. Sholl analysis 
revealed no significant difference between the number of branch intersections up to 170 µm 
away from the soma, stratified by 10 µm increments (Fig 4A). High magnification (60x Obj, 
1.42 NA) images were captured to quantify spine densities. Concurrent with previous findings 
for NrCAM-null dendrites, it was found that basal dendrite spine density was unaffected by the 
L1YH mutation (WT: 4 spines/10 µm, L1YH: 4 spines/10 µm, mean ± SEM), however apical 
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dendrite spine density was significantly increased in the L1YH mice by 27% (WT: 4 spines/10 
µm, L1YH: 6 spines/10 µm, means ± SEM), as shown in Figure 4b. 
Postnatal deletion of Ankyrin B in pyramidal neurons disrupts regulation of spine density 
 
To overcome the early postnatal lethality of germline AnkB deletion, and to explore the 
consequence of postnatal deletion specifically in pyramidal neurons, I generated a conditional 
inducible knockout line. Daily tamoxifen induction of cre recombinase under the Nex1 promoter 
from P10-P13 led to a decreased intensity of AnkB fluorescence in the medial frontal cortex at 
P28 as seen through immunostaining and confocal microscopy (Fig 5A). Background AnkB 
signal in the cKO tissue is due to non-Nex1-expressing neurons and glial cells which did not 
undergo cre recombination. EGFP+ neuronal processes can be seen more readily in the AnkB 
deficient tissue, whereas in the Nex1Cre/RCE control mice, AnkB fluorescence overshadows 
most EGFP signal except for the cell soma. The tamoxifen-specific induction of cre activity was 
validated by immunostaining for EGFP in tamoxifen treated tissue and compared to non-injected 
controls. No EGFP signal is seen in the non-injected controls, compared to the desired mosaic 
labeling in tamoxifen injected brain tissue. The cKO mice displayed no major abnormalities in 
cortical thickness, corpus callosum and anterior commissure thickness, and apparent volume of 
the third vesicle (Fig 5C). To explore the in vivo role for AnkB in dendritic spine remodeling, 
high resolution (63x obj/1.42 NA) confocal images were taken of EGFP+ apical dendrites in the 
medial frontal cortex of AnkB F/F and AnkB +/+ Nex1Cre:RCE mice injected with tamoxifen 
from P10-P13, and harvested at P28 (mid-adolescent) or P50 (young adult). No difference in 
mean spine density was seen between genotypes at P28 (AnkB +/+: 5 spines/10 µm, AnkB F/F: 
5 spines/10 µm, ± SEM), however, there was a 31% increase in mean apical spine density at P50 




Figure 5. Conditional deletion of Ankyrin B in postnatal, post-mitotic pyramidal neurons. (A) Reduced 
immunostaining of AnkB (red) in MFC of P10-P13 tamoxifen injected mice labeled with EGFP reporter in cells 
with Nex1Cre recombination compared to AnkB +/+ (WT alleles). Scale bar = 50 µm. (B) EGFP labeling of MFC 
neurons following induction as in A. White box bounds cg1 cingulate cortex, zoomed in bottom left panel. Bottom 
right panel shows no labeling in uninduced controls, labeled for cortical layers. (C) Major neuroanatomical features 
showing cortical thickness (CT), anterior commissure (AC) and corpus callosum (CC) axon tracts, and volume of 
lateral ventricle (L.V.). Scale bar = 100 µm, 50 µm, 25 µm, and 25 µm top-to-bottom. (D) Early postnatal deletion 
of AnkB has no effect on spine density by early adolescent P21, but causes increased apical spine density by young 
adult P50. Scale bar = 5 µm. (E) Representative quantification of spines represented in D, means ± SEM, n = 2-3 




The molecular mechanisms governing the regulation of dendritic spine numbers during 
development remain incompletely understood. One major mechanism is the crosstalk between 
neurons through the chemorepulsive semaphorin molecules, particularly the secreted class 3 
semaphorins, termed Sema3.6 Previous work has shown a receptor complex for Sema3F on the 
surface of dendritic spines that consists of NrCAM, Neuropilin2, and PlexA3.32 The data 
presented in this chapter demonstrate a critical role for intracellular interactions of the cell 
adhesion molecule NrCAM to correctly refine cortical dendritic spine density, important for 
establishing healthy brain connectivity. I showed that NrCAM binds to cytoskeletal interacting 
proteins Ankyrin B (actin) and DCLK1 (microtubules, signaling) (Fig 1A), and this binding is 
dependent on Tyr1231 residue in the “FIGQY” motif within the cytoplasmic tail (Fig 1C). Upon 
Sema3F docking to the holoreceptor complex, there is a structural rearrangement that occurs, 
termed “clustering,” which allows for the release of auto-inhibition of the PlexA3 intrinsic Rap-
GAP activity inside the cell.31 Unpublished data from our lab have demonstrated a potential 
dual-signaling pathway involving Rac1 signaling, which I hypothesized was achieved initially 
through activation of the GEF Tiam1. I haveve shown that NrCAM indirectly associates with 
Tiam1 in synaptoneurosomes (Fig 1A), potentially through a complex of NrCAM-DCLK1-
Spinophilin-Tiam1. Binding of NrCAM to DCLK1 is dependent on the Tyr1231 residue, as 
single amino acid change to histidine completely eliminates binding (Fig 1C). Further research 
needs to be done to characterize the direct binding of each protein within complex using 
recombinant proteins in vitro.  
In addition to a dual-signaling mechanism initiated by NrCAM, I hypothesized that 
NrCAM binding to the actin cytoskeleton through the spectrin-binding protein Ankyrin B would 
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provide structural support for the clustering action of the receptor complex. Previous studies 
have identified AnkB as a high-confidence autism risk factor,14–17 and an observed phenotype in 
human autism patients is an elevated density of dendritic spines in the cortex,7 further supporting 
our hypothesis. Tyr1229 in the L1 cell adhesion molecule, the homologous tyrosine residue to 
NrCAM Tyr1231, has been shown to regulate binding of L1 to Ankyrin proteins in developing 
axons and retinocollicular targeting.12,33 Phosphorylation of NrCAM Tyr1231 was shown to be 
developmentally dynamic in mouse brain lysates (Fig 1D), although the tyrosine kinase and 
phosphatase that regulate the phosphorylation state remain unknown. This led me to the 
hypothesis that AnkB also interacts with NrCAM, likely through the same residue, as a 
conserved cytoskeletal binding partner for correct localization of neural cell adhesion molecules 
on the surface of the cell. Using high resolution confocal microscopy, I have demonstrated for 
the first time that AnkB is present within the dendritic spine compartment, and co-localizes with 
NrCAM (Fig 1B). Co-immunoprecipitation of AnkB with NrCAM is significantly reduced with 
the Y1231H mutation in cDNA (Fig 1C). Furthermore, rescue of NrCAM-null neurons with the 
Y1231H mutant resulted in a resistance to Sema3F-induced spine retraction (Fig 2A,B). There 
was a loss of holoreceptor clustering following 30 minute Sema3F treatment as demonstrated by 
triple color immunostaining and confocal microscopy of Y1231H-transfected NrCAM-null 
neurons (Fig 2C-F).  
To characterize this mechanism further it would be informative to create a mouse model 
containing the point mutation in NrCAM Y1231 and validate the effect in vivo. Such a mouse 
does not yet exist, however, there is an existing mouse line containing the homologous Y to H 
mutation in L1 Y1229, termed “L1YH.” The L1YH mouse was shown to be deficient for Ank 
binding to L1 and recruitment of Ank to the plasma membrane, which led to an impairment in 
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axon targeting and retinocollicular mapping in the developing mouse.33 It was also found that the 
His1229 L1 mutation led to increased endocytosis of L1, supporting the idea that ankyrins are 
important for structural localization of cell adhesion molecules to the cell surface. Because the 
previous studies were focused on axonal effects, I hypothesized that these mutants would also 
display dendrite phenotypes in the adult cortex, as a result of a malfunctioning adolescent 
refinement period. To address this question, I performed Golgi-Cox staining of adult (P60) 
L1YH mouse brains and wild type littermates to directly label neurons without a fluorescent 
reporter or antibody staining. Whole-cell analysis of pyramidal neuron dendrites in the medial 
frontal cortex revealed no effect on dendritic arborization as quantified through Sholl analysis 
(Fig 4A,B). However, strikingly, there was a significant increase in apical spine density in L1YH 
mutants compared to wild type controls (Fig 4C). Basal spines were not affected. This 
corroborates the findings in cultured neurons from NrCAM-null mice (Fig 2), and further 
suggests the model of cell adhesion molecule binding to the cytoskeletal components for 
dendritic refinement. It will be important to continue exploring this system from a biochemical 
approach, using synaptoneurosome fractionations and cultured neurons in vitro.  
 The binding interaction between NrCAM and DCLK1 is likely to be important for 
downstream Rac1 signaling through Tiam1. Yet, DCLK1 is an established microtubule binding 
protein, and recent studies have implicated a role for microtubules in dendritic spine 
functioning.10 Whereas before it was thought that spines were isolated structures consisting 
solely of filamentous and globular actin, this provides an exciting new mechanism for exploring 
the intracellular mechanisms of the Sema3F holoreceptor. To explore the possibility of 
microtubule requirement for Sema3F spine retraction, I hypothesized that chemical disruption of 
microtubule function would result in an impairment of Sema3F-induced spine retraction. Like 
22 
 
actin, microtubules (MT) exist in a dynamic state of treadmilling tubulin monomers which form 
a microtubule filament. Paclitaxel, a plant alkaloid FDA-approved for cancer chemotherapy, 
binds to beta-tubulin subunits of microtubules and prevents disassembly of the MTs which 
blocks the treadmilling required for healthy functioning. Indeed, treatment of wild type culture 
neurons with 100 nM paclitaxel impaired the ability of Sema3F to induce spine retraction (Fig 
4A). A synthetic antineoplastic agent, nocodazole (NOC), also binds to beta-tubulin in MT 
filaments, but instead of stabilizing the filament, NOC blocks addition of tubulin to the (+) end, 
leading to disassembly of MTs.34 In accord with the experiment with PAC, treatment of wild 
type cultured neurons with 7 µM NOC prior to Sema3F application resulted in a loss of 
sensitivity to Sema3F (Fig 3A). More experiments are needed to explore if chemical disruption 
of MTs impairs Npn2/PlexA3 clustering and RapGAP signaling directly, or if the effects seen 
are further downstream of the receptor complex.  
AnkB is a critical actin-associated protein that is expressed in all mammalian tissues, 
including heart and brain. Germline knockout of AnkB is lethal to 90% of pups by postnatal day 
two.18 Furthermore, it is expressed in non-pyramidal neurons in the brain and in glia. To 
overcome the early postnatal lethality and to explore the consequence of postnatal deletion 
specifically in pyramidal neurons, I generated a conditional inducible knockout line. AnkB 
floxed mice were intercrossed to the Nex1Cre-ERT2 knock-in mouse line, in which a modified 
cre recombinase fused to the estrogen receptor transporter ligand binding domain is under 
control of the Nex1 gene. Temporal knockout of AnkB is achieved by intraperitoneal injection of 
4-hydroxy-tamoxifen (100 mg/kg) to induce nuclear import of the cre recombinase/ERT2 
complex from postnatal day P10-P13, during the major spinogenesis period but prior to 
adolescent spine remodeling. The EGFP-expressing RCE reporter mouse line was also 
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intercrossed for permanent cell-specific labeling of recombinase activity (Fig 5B), which showed 
no “leakiness” of recombination in the absence of tamoxifen. Immunohistochemical analysis of 
AnkB expression in the medial frontal cortex demonstrated reduced AnkB fluorescence in 
induced AnkB F/F Nex1Cre:RCE mice compared to AnkB +/+ controls (Fig 5A). The 
background AnkB signal shown is likely due to non-Nex1 expressing neurons as well as glial 
cells which still produce AnkB. Confocal imaging revealed that postnatal deletion of AnkB 
specifically in pyramidal neurons had no effect on major neuroanatomical features that are 
required for healthy neurodevelopment: cortical thickness, integrity of major axon tracts (corpus 
callosum, anterior commissure), and ventricular volume (Fig 5C). Due to the novelty of this 
transgenic mouse model, it is important to rule out such impairments prior to exploring impaired 
cellular mechanisms. Moreover, high magnification confocal microscopy targeting pyramidal 
neurons in the medial frontal cortex demonstrated an increase in mean spine density of EGFP+ 
(AnkB-null) neurons in the induced AnkB F/F mouse at P50, after the closure of spine 
remodeling in the MFC, yet there was no difference in mean spine density at P25, during the 
peak of adolescent spine remodeling (Fig 5D). This could potentially be due to complementary 
mechanisms in non-Nex1-expressing neurons and glia compensating for the loss of AnkB in 
pyramidal neurons early during adolescence, but by the end of the remodeling phase the loss of 
AnkB becomes apparent. An alternative explanation could be that the spine remodeling phase is 
not one homogenous mechanism, but a collection of distinct mechanisms which show a temporal 
regulation within the spine remodeling phase. Potentially the Sema3F-NrCAM spine remodeling 
and other AnkB-interacting signaling components occurs after P25, and as such no difference is 
seen with loss of AnkB prior to this timepoint. Further experiments need to be conducted to 
delineate the role of timing in vivo. Moreover, an in vitro neuron culture system would be 
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informative for exploring the direct role of AnkB in the Sema3F-NrCAM-Npn2-PlexA3 
holoreceptor complex and downstream RapGAP signaling through PlexA3.  
Elucidating the role that cytoskeletal components DCLK1 and AnkB play in Sema3F-
mediated dendritic spine retraction during development may translate into knowledge about how 
the brain rewires itself on a subcellular mechanistic level. Characterization of the proteins in this 
complex, combined with genetic studies in human neurodevelopmental disorders could present a 
potential target for small molecular drug therapies or the more recent adeno-associated virus 
(AAV) and Crispr/Cas9 gene-editing systems.35–37 As dendritic spines are the major site of 
excitatory signaling in the mammalian brain, it is important to increase our understanding of how 
this system is regulated for establishing healthy connectivity. Too many, as well as too few, 
dendritic spines can have profound effects on human cognition.5 In addition to a decreased 
quality of life for the affected individual and family, it also creates a financial burden for society 
as a whole. Biochemical insights into this process can help to address the gaps in our knowledge 
of how and why these diseases develop, and contribute to our final goal of rescuing healthy 
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CHAPTER TWO: TEMPORAL REGULATION OF DENDRITIC SPINES THROUGH 




Neurocan is a chondroitin sulfate proteoglycan present in perineuronal nets, which are 
associated with closure of the critical period of synaptic plasticity. During postnatal development 
of the neocortex dendritic spines on pyramidal neurons are initially overproduced; later they are 
pruned to achieve an appropriate balance of excitatory to inhibitory synapses. Little is 
understood about how spine pruning is terminated upon maturation. NrCAM (Neuron-glial 
related cell adhesion molecule) was found to mediate spine pruning as a subunit of the receptor 
complex for the repellent ligand Semaphorin 3F (Sema3F). As shown here in the postnatal 
mouse frontal and visual neocortex, Neurocan was localized at both light and electron 
microscopic level to the cell surface of cortical pyramidal neurons and was adjacent to neuronal 
processes and dendritic spines. Sema3F-induced spine elimination was inhibited by Neurocan in 
cortical neuron cultures. Neurocan also blocked Sema3F-induced morphological retraction in 
COS-7 cells, which was mediated through NrCAM and other subunits of the Sema3F 
holoreceptor, Neuropilin-2, and PlexinA3. Cell binding and ELISA assays demonstrated an 
association of Neurocan with NrCAM. Glycosaminoglycan chain interactions of Neurocan were 
required for inhibition of Sema3F-induced spine elimination, but the C-terminal sushi domain 
________________________ 
1 This chapter previously appeared as an article in the journal Frontiers in Cellular Neuroscience. The author 
contributed to immunofluorescence staining and co-immunoprecipitation pull down experiments. The original 
citation is as follows: Mohan V, Wyatt EV, Gotthard I, Phend KD, Duncan BW, Weinberg RJ, Tripathy A, Maness 
PF. (2018) Neurocan inhibits Semaphorin3F induced dendritic spine remodeling through NrCAM in cortical 
neurons. Frontiers in Cellular Neuroscience. 12:346.
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was dispensable. These results describe a novel mechanism wherein Neurocan inhibits  
 
NrCAM/Sema3F-induced spine elimination.  
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Wild type (WT) and NrCAM null mutant mice in the C57BL/6 genetic background were 
maintained in a 12-h day and night cycle environment with ad libitum availability of chow diet 
and water. For labeling postmitotic pyramidal neurons in the cerebral cortex, Nex1-CreERT2 
mice were crossed with the RCE reporter strain (both in C57Bl/6) to generate a tamoxifen-
inducible reporter line of mice expressing EGFP in postmitotic pyramidal neurons under the 
control of Nex1-Cre as previously characterized.1,2 Recombination-induced expression of EGFP 
in postmitotic pyramidal neurons was achieved by daily injections of tamoxifen (100mg/kg in 
sunflower oil) from postnatal day P10-13, as described.1,2 Mice were sacrificed at post-induction 
timepoints using approved methods. All animal experiments were approved by the Institutional 
Animal Care and Use Committee of The University of North Carolina School of Medicine at 
Chapel Hill (IACUC Protocol # 15-114). Mice were handled according to the University of 
North Carolina Institutional Animal Care and Use Committee policies and in accordance with 
NIH guidelines for humane care and use of laboratory animals. 
Immunoblotting 
 
Lysates of mouse cortex (P7, P14, P21, and P80) and cell cultures were prepared in lysis 
buffer (1% Brij98, 10 mM Tris-Cl pH 7.0, 150 mM NaCl, 1 mM NaEDTA, 1 mM NaEGTA, 200 
μM Na3VO4, 10 mM NaF, and 1X protease inhibitors (Sigma-Aldrich). Lysates (50 μg) were 
subjected to Western blotting with the following antibodies: anti-NrCAM (1:1000, Abcam), anti-
Neurocan (1:500, R&D), anti-Sema3F (1:500, Millipore), and anti-β actin (1:1000, Millipore). 
Blots were developed with HRP-tagged secondary antibodies (1:5000, Jackson Immunoresearch) 
using Western Bright ECL Substrate (Advansta) and light sensitive radiometric film exposure. 




For immunostaining, neuronal cultures transfected with pCAGGS-IRES-mEGFP were 
fixed at DIV14 in 4% paraformaldehyde (PFA), permeabilized with Triton X-100, blocked in 
10% horse or donkey serum, and labeled with chicken anti-GFP (Abcam). Secondary anti-
chicken Alexa Fluor 488 antibodies (1:500) were added for 1 h before mounting and confocal 
imaging. For Neurocan localization, 100 μm coronal brain sections were prepared on vibratome 
from Nex1-CreERT2:Ai9 mice (P18 and P80) expressing tdTomato in pyramidal neurons. Serial 
100 μm vibratome sections from P18 and P80 brain were matched for level based on 
rostrocaudal distance from the anterior end of the brain. Samples were blocked in PBS, 10% 
donkey serum, 0.3% Triton X100, then incubated with Neurocan antibodies (1:500, R&D) for 24 
h at 4°C, then with anti-sheep Alexa Fluor 488 secondary antibody (1:500). After washing, 
sections were mounted with Prolong Gold anti-fade reagent (Invitrogen) and imaged using a 
Zeiss LSM 700 confocal microscope. All images were captured using identical microscope 
settings, we kept the total z thickness (7.35 μm) as well as thickness of single optical sections 
(0.35 μm) same for all samples. tdTomato (red) fluorescence was excluded from analysis. The 
intensity of total Neurocan fluorescence observed in the green channel was quantified for each 
image after auto-thresholding without regard to tdTomato fluorescence. Quantification of pixel 
intensity was performed blindly using ImageJ software (NIH). 
Neurocan immunogold labeling and electron microscopy 
 
C57BL/6 WT mice (P18 and P80) were anesthetized and perfused transcardially with 
phosphate buffer (0.15 M sodium phosphate, pH 7.4) and postfixed in 4% PFA, 0.1% 
glutaraldehyde in PBS. Coronal vibratome sections (50 μm) were subjected to pre-embedding 
immunogold labeling with silver enhancement using Neurocan antibodies and streptavidin-
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nanogold (Nanoprobes 2016), as we previously described.3 Sections were silver-enhanced using 
HQ silver enhancement kit (Nanoprobes 2012), and post-fixed in osmium tetroxide. Sections 
were then stained with uranyl acetate and infiltrated with resin. Tissue was sectioned (50–60 
nm), collected on 300 mesh nickel or copper grids, counterstained with uranyl acetate and Sato’s 
lead and examined with a Tecnai 12 transmission electron microscope. 
Spine retraction assay in cortical neuron cultures 
 
Cortical neuronal cultures were prepared from mouse embryos (E15.5) and plated on 
laminin, poly-D-lysine coated chamber slides. Neurons were maintained in neurobasal medium 
(Gibco) supplemented with B27 and antibiotics. Cells were transfected with plasmid pCAGGS-
IRES-mEGFP at DIV11 using Lipofectamine 2000 (Thermo Fisher Scientific). Transfected cells 
at DIV14 were treated with 3 nM Sema3F-Fc (R&D) or Fc (Abcam) for 30 min, the time at 
which spines are maximally retracted.2 Where indicated, cultures were pre-treated for 30 min 
with 8–20 nM full length recombinant human Neurocan (Glu23-Cys1321, R&D) or a mouse 
Neurocan fragment (Asp23-Asp637, R&D), which lacks the C-terminal sushi domain and 
approximately half of the GAG-modified region. Cells were fixed in 4% PFA, permeabilized 
with Triton X-100, blocked in 10% serum, and labeled with anti-GFP to enhance visualization of 
spines. Spine densities were scored on the first branch of multiple apical dendrites using 
Neurolucida software. Spine analysis was blinded. Data was collected from confocal images of 
EGFP-labeled neurons with pyramidal morphology in each of four replicate cultures. Mean spine 
densities ± SEM were compared by the t-test (2-tailed, unequal variances, p < 0.05). To test the 
effect of GAG chain digestion, Neurocan was incubated in solution with 0.1 units/μg 
chondroitinase ABC (chABC, Sigma) at 37°C for 1.5 h, followed by heat inactivation of enzyme 
at 100°C for 10 min. Efficacy of GAG digestion was assessed by immunoblotting. 
33 
 
COS-7 cell retraction assay 
COS-7 cells were plated on eight well chamber slides (25,000 cells/well) coated with 
poly-D-lysine. The following day cells were transfected with plasmids expressing NrCAM 
(pCMV6), Npn2 (pCOS), and/or PlexA3-EGFP (pCAGGS-PlexA3-IRES-mEGFP). At 48 h after 
transfection cells were treated with 3 nM Sema3F-Fc or Fc for 30 min, subjected to 
immunofluorescence staining for GFP and imaged on confocal microscope. The particle tool of 
ImageJ was used after auto-thresholding to measure the area of individual labeled cells. The 
software auto-detects the boundary of cells in thresholded images. Cells between 500 and 1000 
μm2 were classified as retracted (collapsed), and those greater than 1000 μm2 were classified as 
non-retracted. The mean percent of collapsed cells relative to the total GFP-positive cells was 
calculated from three experiments, 10 images per condition, and compared by the t-test for 
significant differences (∗p < 0.05, n = 3 from ∼200 cells/image). Preliminary dose response 
experiments showed that Neurocan (4–40 nM) effectively inhibited the Sema3F-Fc-induced 
COS-7 cell retraction response; we selected 8 nM for subsequent studies. 
Cell binding and ELISA assays 
COS-7 cells were transfected with NrCAM in pCMV6 or vector alone, together with 
pCAGGS-IRES-mEGFP. Cortical neurons from NrCAM homozygous null mice were 
transfected on DIV11 with pCAGGS-NrCAM-IRES-mEGFP or vector alone. At 48 h post-
transfection, cells were treated with 20 nM recombinant Neurocan at 37°C for 30 min. To assay 
Neurocan binding to the cell surface, cultures were fixed and subjected to indirect 
immunofluorescence staining with antibodies to Neurocan and secondary Alexa Fluor-
conjugated antibodies. Single optical section images were taken on the confocal microscope 
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using the same settings for each condition, and the fluorescence intensity of staining measured 
using Image J. 
ELISA was performed to measure the binding between NrCAM-Fc (R&D) and alkaline-
phosphatase-tagged Neurocan (Neurocan-AP). The Neurocan-AP fusion protein construct was 
generated by PCR amplification of full-length mouse Neurocan cDNA (Accession: BC065118), 
followed by subcloning into the APtag5 vector so that the alkaline phosphatase (AP) tag was 
inserted at the N-terminus of Neurocan.4 Neurocan-AP or AP control proteins were harvested 
from conditioned media of HEK293T cells transfected with Neurocan-APtag5 or APtag5 
plasmids after 72 h. Media was clarified by centrifugation and filtered through a 0.45 μm filter. 
Detailed methods of APtag5 protein production have been described.5 The ELISA was carried 
out essentially as described for Neurocan-AP binding to protein tyrosine phosphatase sigma.4 
Protein A plates (Pierce) were coated with 1 μM NrCAM-Fc or Fc in HBSS-20 mM HEPES, pH 
7.0 for 2 h at room temperature. Blocking was performed with SuperBlock (Thermo Fisher 
Scientific). After washing in HBSS-20 mM HEPES, wells were incubated with 10 μM 
Neurocan-AP or AP for 1.5 h at RT. Reaction product was developed using p-
nitrophenylphosphate to detect AP activity. Optical density measurements were taken at 405 nm 
on an ELISA plate reader. 
To assess direct binding of Neurocan with semaphorins, 1 μg of full length recombinant 
Neurocan (R&D) was incubated with 1 μg of either control Fc, Sema3A-Fc, or Sema3F-Fc in 
Tris-buffered saline for 1 h at 37°C. Protein A/G Sepharose beads were used to pull down Fc 
proteins for detection of bound Neurocan by immunoblotting with Neurocan antibodies. Blots 






Expression and localization of Neurocan in the frontal and visual cortex 
To evaluate the postnatal expression of Neurocan in developing mouse brain, cortical 
lysates were analyzed at P7, P14, P30, and adult by Western blotting. Neurocan was detected as 
a broad band from 150 to 250 kDa reflecting GAG-modification (Fig. 6A). Quantification 
showed that Neurocan expression in the cortex increased markedly (∼8 fold) from P7 to P14, 
declined at P30, and persisted in adulthood (Fig. 6A,B). The level of Sema3F (90 kDa) in the 
developing cortex paralleled that of Neurocan with a ∼6 fold increase from P7 to P14 then a 
decrease with maturation (Fig. 6A,B). To determine if Neurocan was localized to cortical 
pyramidal neurons at adolescent (P18) and adult (P80) stages, immunofluorescence staining for 
Neurocan was performed in the medial frontal cortex (MFC) and primary visual cortex (V1). 
These cortical regions have been shown to be sites of spine density regulation on apical dendrites 
of pyramidal neurons by Sema3F and NrCAM/Npn2/PlexA3.2 To identify pyramidal neurons, 
we used a tamoxifen-inducible reporter line of mice expressing tdTomato specifically in 
postmitotic pyramidal neurons under the control of Nex1-CreERT2 promoter.1,2 At both P18 and 
P80, Neurocan labeling in the MFC and V1 was prominent around cell bodies and processes of 
tdTomato-positive pyramidal neurons throughout the cortical layers, in addition to other cells 
(Fig. 6C). Nonimmune IgG (IgG) staining was negligible. The intensity of Neurocan 
immunofluorescence (green channel only, excluding tdTomato) was quantified in coronal 
sections matched for level from confocal images obtained under identical settings. Neurocan 
immunofluorescence levels throughout the cortical layers were significantly greater at P18 than 




Figure 6: Expression of Neurocan in developing mouse neocortex. (A) Representative immunoblots of Neurocan 
and Sema3F in lysates of cerebral cortex (50 µg) from postnatal (P7, P14, P30) and adult brain (A). β-Actin served 
as loading control. (B) Relative levels of Neurocan and Sema3F in cerebral cortex (A) at each developmental stage 
(n=3) normalized to β-actin. Means ± SEM are shown. (C) Immunofluorescence staining for Neurocan (green) and 
tdTomato (red) in coronal sections from MFC and V1, layer 4 in Nex1-CreERT2:Ai9 mice at adolescent (P18) and 
adult (P80) stages. Nonimmune IgG control is shown as an inset. Cortical layers are numbered. Scale bar = 50µm. 
(D) Fluorescence intensity of Neurocan immunostaining in MFC and V1 at P18 and P80 (n=10 images for each 
condition from 3 brains). Mean differences (± SEM) in Fc versus Sema3F-Fc treated cultures were compared for 
significance (*t-test, p<0.05). (E) Representative image showing Neurocan immunostaining (green) surrounding 
tdTomato-positive pyramidal neurons in V1, of Nex1-CreERT2:Ai9 mice. Scale bar = 50 µm. (F) High 
magnification of E. Upper panel, normal IgG; lower panel, Neurocan immunostaining (green) around dendrites with 
spines (scale bar = 10µm). Far right panel shows magnified view of boxed area.  
 
of pyramidal neurons at P18 in the MFC appeared to be diffusely localized around soma, 
dendrites, and extracellular space (Fig. 6E). Neurocan was also evident as a diffuse net at or near 
the membrane of dendritic branches, including in the vicinity of dendritic spines (arrows, Fig. 
6F). 
 The subcellular localization of Neurocan was investigated in greater detail in the MFC by 
37 
 
immunogold labeling at the electron microscope level. At P18, labeled Neurocan was observed 
near the neuronal membrane adjacent to excitatory, asymmetric synapses of dendritic spines (Sp; 
Fig. 7A, arrows) but it was not found directly within synaptic junctions. Neurocan was also 
evident at the membrane or extracellular space, and could be seen near presynaptic axon 
terminals (AT), which harbored synaptic vesicles (Fig. 7A,B,D, arrows). Neurocan labeling was 
frequently clustered at or near dendritic membranes as well as the extracellular space (Fig. 7C, 
arrows). At P80, Neurocan was observed at the plasma membrane near spines, and sometimes 
adjacent to asymmetric, excitatory synapses (Fig. 7E). At both stages labeling was rarely present 
within the cytoplasm. The appropriate dilution of Neurocan antibodies and specificity was pre-
assessed by immunoperoxidase staining of COS-7 cells transfected with plasmids expressing 
Neurocan-AP or control AP protein. Cells expressing Neurocan-AP were clearly stained with 
Neurocan antibodies, whereas cells expressing AP elicited minimal staining, as did omission of 
primary antibody (Fig. 7F). In summary, Neurocan was expressed prominently in the postnatal 
MFC and V1, declining with maturation, and was localized near the plasma membrane of 
pyramidal cell processes and adjacent to dendritic spines. 
Neurocan inhibits Sema3F-induced spine and cell retraction 
 
To assess the potential of Neurocan to terminate spine remodeling during postnatal 
maturation, we tested the ability of Neurocan to inhibit Sema3F-induced spine retraction in 
cortical neurons in culture. In this assay,2,6 dissociated cortical neurons from mouse embryos at 
E15.5 were transfected with pCAGGS-IRES-mEGFP at DIV11 and cultured to DIV14. Cells 
were pre-treated with or without Neurocan for 30 min, then stimulated with 3 nM Sema3F-Fc or 
Fc protein for 30 min. We used a concentration of Neurocan (20 nM) that exceeded the Kd for 




Figure 7: Localization of Neurocan in mouse medial frontal cortex (MFC) by immunogold labeling and electron 
microscopy. (A) Electron micrograph of MFC layer 2/3 at P18, showing immunogold labeling of Neurocan near the 
plasma membrane adjacent to a spine (Sp) and axon terminal (AT) (arrows). (B) Neurocan labeling in the 
extracellular space near an axon terminal (AT; arrow) at P18. Nucleus (Nuc), cytoplasm (Cyto). (C) Accumulation 
of Neurocan (arrows) in extracellular space and along the plasma membrane of a dendrite (D) at P18. Mitochondria 
(M) were unlabeled. (D) Neurocan labeling adjacent to axon terminals (AT) at P18. (E) Neurocan labeling at neck of 
spine (Sp) and near excitatory synapses (arrows) at P80. Scale bar = 1µm. (F) Validation of Neurocan antibody 
specificity by immunoperoxidase staining of COS-7 cells transfected with Neurocan-AP or AP alone in the APtag5 
vector, using Neurocan antibodies or no primary antibody. An antibody dilution series was carried out in pilot 
experiments.  Scale bar = 50 μm. 
 
retraction in cortical neuron cultures,3 and was within the estimated physiological range in rodent 
brain, which varies with age and region.9,10 Analysis of spine density on apical dendrites of 
EGFP-labeled neurons showed that Neurocan (20 nM) blocked Sema3F-induced spine retraction, 




Figure 8: Neurocan inhibits Sema3F-induced spine and cell retraction. (A) Apical dendrites and spines of mouse 
cortical neurons expressing EGFP in cultures treated with Fc or Sema3F-Fc for 30 min. Pretreatment with 20 nM 
Neurocan for 30 min prevented Sema3F-Fc induced spine collapse but did not affect spine density in Fc-treated 
control cultures. Scale bar = 10µm. (B) Quantification of experiment in panel A, showing significant reduction in 
mean spine density upon Sema3F-Fc treatment by Neurocan (n=3, 10 neurons per condition; *p<0.05, t- test).  
(C) Treatment with 8 nM Neurocan for 30 min also prevented Sema3F-Fc induced spine collapse and did not affect 
spine density in Fc-treated control cultures (n=3, 10 neurons per condition; *p<0.05, t- test). (D) Representative 
thresholded images showing morphological retraction of COS-7 cells expressing NrCAM, Npn2, PlexA3 and EGFP 
after Sema3F-Fc treatment compared to Fc. Arrows point to retracted cells. Scale bar = 100µm. (E) Quantification 
of morphological cell retraction after Fc or Sema3F-Fc treatment of COS-7 cells expressing NrCAM, Npn2, and/or 
PlexA3 and EGFP in panel A. Results show percent retracted cells (n=3 assays, *p<0.05, t test). (F) Quantification 
of morphological retraction upon Fc or Sema3F-Fc treatment of COS-7 cells expressing NrCAM, Npn2, and PlexA3 
with and without pre-treatment with 20 nM Neurocan for 30 min (n=3 assays, *p<0.05, t test).   
 
cultures with a lower spine density were obtained using a lower concentration of Neurocan (8 
nM) (Fig. 8C). 
To evaluate the molecules involved, we used a heterologous assay in which 
morphological retraction of COS-7 cells can be induced by Sema3A-Fc or Sema4D-Fc.11 COS-7 
cells were transfected with one or more plasmids expressing NrCAM, Npn2, PlexA3, then 
treated with 3 nM Sema3F-Fc or Fc for 30 min. COS-7 cells expressing all three Sema3F 
holoreceptor subunits NrCAM, Npn2, and PlexA3, showed the highest percent of retracted cells 
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after treatment with Sema3F-Fc compared to Fc (Fig. 8D,E). Cells expressing only Npn2 and 
PlexA3 also retracted upon Sema3F-Fc treatment but required NrCAM for maximal response 
(Fig. 8E). Significant retraction was not observed in COS-7 cells expressing Npn2 or PlexA3 
alone, or in cells doubly expressing NrCAM/Npn2 or NrCAM/PlexA3 (Fig. 8E). Cells 
expressing only EGFP also did not respond to Sema3F-Fc (Fig. 8F). A basal level of retracted 
cells was observed in each condition (25–30%), which may be due to changes in shape as a result 
of mitosis, migration, or cell heterogeneity. To determine if Neurocan negatively regulated 
Sema3F-induced cell retraction, COS-7 cells expressing NrCAM/Npn2/PlexA3 were pre-treated 
with 8 nM Neurocan, then stimulated with 3 nM Sema3F-Fc or Fc. Neurocan effectively blocked 
NrCAM/Npn2/PlexA3-dependent retraction to Sema3F-Fc (Fig. 8F). These results demonstrated 
that Neurocan negatively regulates Sema3F-induced retraction through a mechanism involving 
the NrCAM/Npn2/PlexA3 receptor complex. 
NrCAM-dependent binding of Neurocan 
We hypothesized that Neurocan negatively regulates Sema3F-mediated retraction by 
binding to the extracellular region of NrCAM at the cell surface. To test this, we examined the 
ability of Neurocan to bind to COS-7 cells transfected with NrCAM or vector alone, together 
with EGFP. COS-7 cells were treated 48 h post-transfection with or without 20 nM Neurocan for 
30 min. Cells were washed extensively, fixed without permeabilization, and subjected to 
immunofluorescence staining with Neurocan antibodies. The amount of surface-bound Neurocan 
on EGFP-labeled cells was quantified by measuring the fluorescence intensity of Neurocan 
staining in single optical sections. Results showed that Neurocan bound at greater levels to the 
surface of cells that expressed NrCAM compared to cells without NrCAM transfected with 
vector alone (Fig. 9A,B). The low level of fluorescence seen in untreated cells was likely 
nonspecific. Immunoblotting for Neurocan and GAPDH (loading control) in lysates of similarly 
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treated cells, showed that Neurocan was detected in cells transfected with the NrCAM plasmid 
but not in control cells without NrCAM (Fig. 9C). 
To determine if Neurocan bound to neuronal cells expressing NrCAM, cortical neuron 
cultures from homozygous NrCAM null mutant embryos (E15.5) were transfected at DIV11 with 
pCAGGS-IRES-mEGFP or pCAGGS-NrCAM-IRES-mEGFP, and treated at DIV14 with 20 nM 
Neurocan for 30 min. After washing and fixation without permeabilization, neurons were 
immunostained to detect Neurocan on the cell surface. EGFP-labeled neurons expressing 
NrCAM exhibited a greater amount of surface-bound Neurocan than NrCAM-minus neurons, 
and quantitation showed that this difference was significant (Fig. 9D,E). The lower level of 
Neurocan fluorescence on NrCAM-minus neurons may be due to interaction with other binding 
proteins on the cell surface. Results of the cell binding assays showed that expression of NrCAM 
leads to increased binding of Neurocan to the cell surface. To assess a direct interaction of 
Neurocan with the NrCAM extracellular region, we developed an ELISA using purified, full-
length mouse Neurocan fused to AP expressed in HEK293T cells. NrCAM-Fc protein was 
adsorbed to ELISA plates that were pre-coated with Protein A, then incubated with Neurocan-AP 
or AP control protein for 1.5 h. Binding was quantified by colorimetric detection of bound AP 
using p-nitrophenylphosphate. As a positive control, Neurocan-AP was also assayed for binding 
to NCAM, a different cell adhesion molecule known to engage Neurocan at its extracellular Ig2 
domain.3 Neurocan-AP bound to NrCAM-Fc to a significantly greater extent than control AP 
(Fig. 9F). Similar levels of Neurocan-AP binding to NCAM-Fc were observed. Taken together, 
these results support the conclusion that Neurocan binds to the extracellular region of NrCAM 





Figure 9: Cell binding and Neurocan interaction with NrCAM. (A) COS-7 cells transfected with vector alone 
(pCAGGS-IRES-mEGFP) or pCAGGS-NrCAM-IRES-mEGFP were pre-treated with 8 nM Neurocan, then fixed 
and subjected to immunofluorescence staining without permeabilization to detect surface-bound Neurocan (red). 
Scale bar= 100 µm. (B) Mean fluorescence intensity (± SEM) of Neurocan immunofluorescence staining on the 
surface of COS-7 cells, as shown in panel A. NrCAM-expressing cells treated with Neurocan showed significantly 
greater levels of bound Neurocan than untreated cells. Fluorescence intensity in cells with vector alone treated with 
Fc or Sema3F-Fc was non-significant (ns). (*p>0.05, t test, n= 5 images each condition). (C) Lysates (50 µg) of 
cells transfected with vector alone or pCAGGS-NrCAM-IRES-mEGFP were treated with Neurocan as in panel A, 
and immunoblotted (IB) with Neurocan antibodies. Blots were reprobed with antibodies directed against GAPDH 
(loading control) or NrCAM (expression control). Representative immunoblots of 3 experiments are shown. (D) 
Mouse cortical neuron cultures from NrCAM null mice were transfected with vector alone or pCAGGS-NrCAM-
IRES-EGFP, and pre-treated with 20 nM Neurocan before fixation and immunostaining to detect surface-bound 
Neurocan. In merged images of EGFP (green) and Neurocan (red), more Neurocan immunofluorescence was 
observed on the surface of neurons expressing NrCAM than on NrCAM null neurons with vector alone. (Scale bar= 
50 µm). (E) Mean fluorescence intensity (± SEM) of surface-bound Neurocan immunostaining on neurons in panel 
D. NrCAM-expressing cells treated with Neurocan showed significantly greater levels of bound Neurocan than 
NrCAM-minus neurons.  (*p>0.05, t-test, n= 10 neurons per condition). (F) ELISA of Neurocan-AP or control AP 
protein binding to NrCAM-Fc or positive control NCAM-Fc on protein A-coated microtiter wells. AP binding was 
detected colorimetrically with p-nitrophenylphosphate.  The mean (± SEM) optical densities (OD 405) of Neurocan-
AP bound to NrCAM-Fc or NCAM-Fc were significantly greater than control AP (t-test, *p>0.05). (G) 
Recombinant human Neurocan was incubated in Tris buffered saline with purified Fc, Sema3F-Fc, or Sema3A-Fc 
proteins, then complexes were pulled down with Protein A/G Sepharose beads. Immunoblotting for Neurocan 
showed no binding of Neurocan to Fc or Sema3F-Fc, whereas Neurocan bound effectively to Sema3A-Fc. Blots 
were reprobed with anti-Fc antibodies to demonstrate that equivalent amounts of Fc fusion proteins were pulled 




Sema3A is a class 3 semaphorin that has been reported to bind to chondroitin sulfates in 
PNNs but has not been shown to bind Neurocan.12,13 The possibility of sequestration of  
Sema3F-Fc by Neurocan was tested by incubating Sema3F-Fc, Sema3A-Fc, or Fc proteins in 
Tris buffered saline (TBS) with purified recombinant mouse Neurocan in vitro. Fc-containing 
protein complexes were pulled down with Protein A/G-Sepharose and subjected to Western 
blotting to detect Neurocan present in the Protein A/G pull-downs. Results showed that 
Neurocan bound to Sema3A-Fc, but there was no detectable association with Sema3F-Fc or Fc 
alone (Fig. 9G). Reprobing blots with anti-Fc antibodies confirmed that pull-downs contained 
approximately equivalent amounts of Fc-containing protein. 
Importance of Neurocan GAG chains in regulation of spine retraction 
 
CSPGs have been shown to restrict plasticity of cortical and hippocampal neurons, and digestion 
of their associated GAG chains with chondroitinase ABC (chABC) increases spine dynamics and 
density.14-16 Therefore, we postulated that Neurocan GAG chains may be critical for inhibiting 
Sema3F-induced spine retraction. To test this hypothesis, GAG chains present on recombinant 
Neurocan were digested with chABC, as described.3 Chondroitinase-digested Neurocan was 
compared with untreated Neurocan for inhibition of Sema3F-Fc induced spine retraction in 
cortical neuron cultures. Results showed that chABC-treated Neurocan (20 nM, 30 min) did not 
block Sema3F-induced spine retraction, whereas untreated Neurocan effectively inhibited spine 
retraction compared to the untreated control (Fig. 10A,B). GAG removal from Neurocan was 
confirmed on Western blots by a shift in GAG-modified Neurocan to lower molecular weight 
and band narrowing (Fig. 10C). 
Neurocan binds to the related adhesion molecule L1 through the C-terminal sushi 




Figure 10: Enzymatic digestion of Neurocan GAG chains with chondroitinase ABC decreases its ability to inhibit 
Sema3F-induced spine retraction. (A) Images showing spines on apical dendrites from cortical neurons (EGFP, 
green) in culture treated with Fc or Sema3F-Fc.  Neurocan blocked Sema3F-mediated spine retraction, whereas 
chABC-treated Neurocan was not effective. Scale bar = 10µm. (B) Quantification of experiment in panel A shows a 
significant reduction in mean spine density of control neurons treated with Sema3F-Fc compared to Fc.  Sema3F-
induced spine retraction was fully blocked by 20 nM Neurocan, as well as by chABC-digested Neurocan *p<0.05, t 
test; n=3, 10 neurons per condition). (D) Immunoblotting of Neurocan before and after treatment with chABC to 
remove GAG chains. A shift in apparent molecular size of chABC-treated Neurocan was observed, reflecting a 
decrease in GAG content. (D) Mouse cortical neurons with and without pre-treatment with recombinant mut 
Neurocan lacking the C-terminal sushi domain (20 nM, 30 min) showed the mouse Neurocan fragment inhibited 
Sema3F-Fc induced spine retraction. (E) Model showing that interaction of the PNN protein Neurocan with NrCAM 
on the surface of dendritic spines in cortical pyramidal neurons terminates Sema3F-induced dendritic spine 
remodeling during postnatal maturation. Neurocan core protein is depicted in green with yellow GAG chains. The 
Sema3F receptor complex is comprised of NrCAM (yellow), Npn2 (blue) and PlexA3 (red) subunits. 
of the Neurocan sushi domain in NrCAM-mediated spine retraction, a recombinant mouse 
Neurocan fragment lacking the sushi domain (mutNeurocan) was assayed for inhibition of 
Sema3F-induced spine retraction in cortical neuron cultures. Neurocan lacking the sushi domain 
effectively inhibited Sema3F-mediated spine retraction, indicating that NrCAM, unlike L1, does 





We report here that Neurocan, one of the first CSPGs to be expressed in the maturing 
neocortex18 is expressed coordinately with Sema3F in postnatal and adult mouse brain in close 
apposition to dendritic spines and axon terminals. Neuronal spine retraction and cell binding 
studies showed that Neurocan interacts with NrCAM and inhibits Sema3F-mediated dendritic 
spine elimination, providing insight into the molecular basis of PNN-mediated restriction of 
synaptic plasticity. Our results support a model (Fig. 10E) in which NrCAM/Npn2/PlexA3 
functions as a holoreceptor complex for Sema3F that prunes excess dendritic spines from 
pyramidal neuron subpopulations during postnatal stages of active spine remodeling in the 
cerebral cortex. As PNNs arise during subsequent maturation, Neurocan within the PNN 
meshwork interacts with NrCAM on dendritic spines to terminate Sema3F-mediated spine 
pruning. 
In postnatally developing areas of the mouse neocortex (MFC and V1), Neurocan was 
localized around processes, spines, and soma of Nex1-expressing postmitotic pyramidal neurons, 
then declined to lower levels in adulthood. As shown by immuno-electron microscopy of the 
frontal cortex (P18), Neurocan was prominent at plasma membranes and extracellular space, 
often in proximity to spines, axon terminals, and postsynaptic densities. Previously, we showed 
that Neurocan was also localized to perisomatic axon terminals and soma of inhibitory 
interneurons in the MFC.3 The present findings are in agreement with PNN localization at the 
surface of pyramidal cells in adult rat V1 and MFC19 and near dendritic spines in mouse 
hippocampus. In a functional assay for Sema3F signaling in cortical neuron cultures, we found 
that Neurocan inhibited spine retraction on apical dendrites of pyramidal neurons. Similarly, in a 
model cell assay for Sema3F-induced repulsion, Neurocan inhibited morphological retraction 
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through Sema3F receptor subunits NrCAM, Npn2, and PlexA3. Our culture experiments are in 
accord with two-photon live imaging studies in adult mouse visual cortex, which demonstrated 
that CSPGs inhibited spine dynamics and constrained spine morphology, and these effects were 
reversed by GAG chain degradation.14,16 The present findings suggest that Neurocan, possibly in 
conjunction with other CSPGs may contribute to terminating the highly active spine remodeling 
of juvenile cortical pyramidal neurons during the transition to adulthood. 
Cell binding and ELISA assays showed that Neurocan was able to bind NrCAM within 
its extracellular region, which engages in homophilic and heterophilic interactions. chABC 
perturbed the ability of Neurocan to block Sema3F-mediated spine pruning in cultured neurons, 
indicating that GAG chains mediated this inhibition. Our binding results with recombinant 
proteins support radioimmunoassay studies showing binding of full length NrCAM purified from 
mouse brain to Neurocan.8,20 Our experiments with the NrCAM extracellular domain protein 
fused to Fc further demonstrate that Neurocan interacts with the extracellular region of NrCAM 
sufficiently to impair neuronal function. 
A limitation of the present work is that it is not known how NrCAM association with 
Neurocan inhibits spine remodeling, such as by altering upstream interactions or downstream 
signaling. Our results clearly showed that Neurocan did not interact with the upstream ligand 
Sema3F. Unlike Sema3A, which associates with the CSPGs versican and aggrecan in the brain 
extracellular matrix.21 Sema3F-Fc did not bind purified Neurocan, thus upstream sequestration of 
Sema3F is unlikely be responsible for inhibiting spine remodeling. We recently reported that 
NrCAM, Npn2, and PlexA3 form a complex for Sema3F required for spine retraction.2 Neurocan 
binding might alter the conformation of NrCAM within the holoreceptor complex to prevent 
Sema3F-induced changes in receptor function. Such an alteration could be subtle, because 
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Neurocan did not perturb the ability of NrCAM to co-immunoprecipitate with Npn2 from 
transfected HEK293 cells (not shown). The carboxy-terminal sushi domain of Neurocan, which 
mediates binding to L1-CAM17 was dispensable for inhibiting NrCAM-dependent spine 
retraction, suggesting a different mode of binding to NrCAM. Currently, little is known about 
Sema3F-induced signaling through PlexA3 in dendritic spines, future studies will be needed to 
address the possibility that Neurocan influences downstream pathways. 
Neurocan and other CSPGs in PNNs have been reported to associate with Ig-class 
adhesion molecules, including NCAM, L1, NgCAM, Neurofascin, and TAG1, as well as 
integrins.8,17,22,23 Thus, Neurocan could have multiple targets in developing neurons, some of 
which may contribute to spine remodeling. For example, an inhibitory role for Neurocan was 
recently identified in terminating postnatal remodeling of GABAergic axon terminals in 
prefrontal cortex to stabilize perisomatic inhibitory synapses.3 Neurocan binds the NCAM Ig2 
domain and competitively inhibits NCAM-EphA3 association to prevent ephrinA5/EphA3 
signaling and axonal repulsion. 
An inhibitory function of Neurocan in Sema3F-mediated spine pruning in the adolescent 
brain, suggested by our in vitro studies, might serve to protect a subpopulation of cortical 
pyramidal neurons from over-pruning of dendritic spines. Other mechanisms of synaptic 
elimination involve astrocyte-mediated phagocytosis through engulfment receptors (MerTK and 
MEGF10), microglia-mediated pruning (C1q, C3, and CX3CR1)24 and autophagy through 
mTOR signaling.25 The involvement of Neurocan in regulating synapse remodeling on both 
excitatory and inhibitory neurons makes it an important candidate molecule for 
neurodevelopmental disorders with aberrant spine and synapse numbers that could impact 
cortical excitatory/inhibitory balance. In schizophrenia, PNNs are notably altered in human 
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prefrontal cortex26 where dendritic spine density is markedly diminished27-30 and Neurocan is a 
candidate locus for schizophrenia, bipolar, and other neurological disorders.31-34 
In conclusion, we provide evidence that the PNN protein Neurocan acts as a 
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APPENDIX ONE: PERINEURONAL NET PROTEIN NEUROCAN INHIBITS 




 Perineuronal nets (PNNs) are implicated in closure of critical periods of synaptic 
plasticity in the brain, but the molecular mechanisms by which PNNs regulate synapse 
development remain obscure. A receptor complex of NCAM and EphA3 mediates postnatal 
remodeling of inhibitory perisomatic synapses of GABAergic interneurons onto 
pyramidal cells in the mouse frontal cortex necessary for excitatory/inhibitory balance. 
Here it is shown that enzymatic removal of PNN glycosaminoglycan chains decreased 
the density of GABAergic perisomatic synapses in mouse organotypic cortical slice 
cultures. Neurocan, a key component of PNNs, was expressed in postnatal frontal 
cortex in apposition to perisomatic synapses of parvalbumin-positive interneurons. 
Polysialylated NCAM (PSA-NCAM), which is required for ephrin-dependent synapse 
remodeling, bound less efficiently to neurocan than mature, non-PSA-NCAM. Neurocan 
bound the non-polysialylated form of NCAM at the EphA3 binding site within the 
immunoglobulin-2 domain. Neurocan inhibited NCAM/EphA3 association, membrane 
clustering of NCAM/EphA3 in cortical interneuron axons, EphA3 kinase activation, and 
ephrin-A5-induced growth cone collapse. These studies delineate a novel mechanism 
wherein neurocan inhibits NCAM/EphA3 signaling and axonal repulsion, which may 
terminate postnatal remodeling of interneuron axons to stabilize perisomatic synapses 
in vivo.  
__________________ 
1 This chapter previously appeared as an article in the journal Scientific Reports. The author contributed to 
immunofluorescence staining and pull-down binding experiments. The original citation is as follows: Sullivan CS, 
Gotthard I, Wyatt EV, Bongu S, Mohan V, Weinberg RJ, Maness PF. (2017) Perineuronal net protein Neurocan 




MATERIALS AND METHODS 
 
Mice 
Mice were used according to the University of North Carolina Institutional Animal 
Care and Use Committee (IACUC) policies (AAALAC Institutional Number: #329) and in 
accordance with NIH guidelines, and all animal protocol procedures were approved by 
the University of North Carolina IACUC (IACUC ID# 15-243). The Pvalb-IRES-Cre line1 (JAX 
No. 008069) was crossed to the Ai9 reporter line2 (JAX No. 007909) to label 
cells with tdTomato after Cre-mediated recombination. Mice were maintained on the 
C57BL/6 background.  
Immunochemicals and reagents 
Monoclonal antibodies used were directed against NCAM (OB11; Sigma Aldrich), 
phosphotyrosine (PY99; Santa Cruz Biotechnology), versican (sc-47769, Santa Cruz 
Biotechnology), C-4-S (MAB2030, Millipore Sigma), and PSA (Ab5324, Millipore). An 
antibody recognizing a shared epitope of aggrecan and brevican (sc-166951, Santa Cruz 
Biotechnology) was also used. Polyclonal antibodies were against neurocan (AF5800, R&D), 
EphA3 (C-19; Santa Cruz Biotechnology), NCAM (H300; Santa Cruz Biotechnology), GAPDH 
(IMG-3073, Imgenex), GABA (A2052; Sigma and ab17413; Abcam), GAD65 (GAD-6; 
Developmental Studies Hybridoma Bank), MATH-2 (ab85824; Abcam), and GFP (13970; 
Abcam). Normal rabbit IgG and goat anti-human IgG were from Jackson ImmunoResearch 
Laboratories. Secondary antibodies from Life Technologies were antimouse Alexa-488, anti-
mouse Alexa-555, anti-mouse Alexa-647, anti-rabbit Alexa-555, and anti-rabbit Alexa-647. 
Other secondary antibodies used were anti-guinea pig Alexa-405 (Sigma Aldrich), anti-rabbit 
Alexa-405 (Abcam), anti-human IgG-HRP (Sigma-Aldrich), anti-mouse-HRP (Pierce), anti-
goat-HRP (Southern Biotech), and donkey anti-rabbit HRP (Sigma-Aldrich). Labeling of PNNs 
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was performed using biotinylated Wisteria Floribunda Agglutinin (WFA) (L1766; Sigma) and 
streptavidin-Alexa-647 (S32357; ThermoFisher). Recombinant ephrin-A5-Fc, human Fc, mouse 
neurocan, human neurocan, and human tenascin-R (R&D Systems) were also used. Human 
NCAM-Fc proteins3 were purified from transfected HEK293T cell conditioned media using 
Protein A Sepharose (Pierce). Chondroitinase ABC and penicillinase were purchased from 
Sigma Aldrich. Endoneuraminidase-N (endo-N), which removes α-2,8 sialic acid chains,4 was a 
gift of Urs Rutishauser (Memorial Sloan-Kettering Cancer Center).  
Enzymatic treatment of organotypic brain slices 
 
Organotypic slice cultures containing the PFC were prepared by sectioning the brain of 
PV-Cre;Ai9 mice at age P5 in the coronal plane (400 μm).5 Slices were cultured in Millicell 
tissue culture inserts in Dulbecco's Modified Eagle's Media (DMEM) containing 20% horse 
serum, 1 mM L-glutamine, 13 mM D-glucose, 1 mM CaCl2, 2 mM MgSO4, 1 μg/mL insulin, 30 
mM HEPES, 5 mM NaHCO3, and 0.001% ascorbic acid, which was replaced every 2 days as 
described.6 Slices at 12 days in vitro (DIV) were treated with chABC (0.2U/mL) or control 
penicillinase (0.2U/ml) for 2 hours,7 followed by 2 rinses with culture media to remove enzyme 
and another 2 days of culture before fixation on DIV14. Slices were fixed in 4% PFA and stained 
with antibodies to NeuN to mark neuronal nuclei (1:400),8 tdTomato to label perisomatic puncta 
(1:100), and biotinylated WFA to label PNNs (1:500) followed by detection with streptavidin-
Alexa647. A blinded observer scored the average number of perisomatic puncta within 2 μm of 
NeuN-labeled nuclei from 3 animals per enzymatic treatment condition (30 cells/condition). The 
efficiency of chABC treatment was verified by imaging WFA labeling compared to the control 
condition (penicillinase-treated). For rescue experiments, slices were treated with enzyme at DIV 
12 for 2 hours, rinsed twice with culture media, and then cultured in media containing no added 
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protein (control untreated), recombinant neurocan (20 μg/ml), or recombinant tenascin-R (20 
μg/ml) until fixation on DIV 14.  
Electron microscopy and immunogold labeling 
 
C57BL/6 WT mice were anesthetized and perfused transcardially with phosphate 
buffered saline (PBS) followed by 4% PFA + 0.1% glutaraldehyde in PBS. Brains were 
postfixed for 2 days in the same fixative, and 50 μm thick coronal sections were cut using a 
vibratome. Pre-embedding immunogold labeling with silver enhancement was performed for 
neurocan. To quench glutaraldehyde, sections were pretreated with 1% NaBH4 in PBS and then 
3% H2O2 in PBS, followed by blocking in 10% normal donkey serum. Sections were incubated 
overnight in primary antibody diluted at 1:500-1:2000 in PBS, rinsed, briefly re-blocked in 2% 
normal donkey serum, and incubated for 2 hours in biotinylated donkey anti-sheep secondary 
(Jackson ImmunoResearch 713-065-147). Samples were rinsed and incubated 1 hour in 
streptavidin-nanogold (Nanoprobes 2016) at 1:100 in 1% normal donkey serum/PBS. Sections 
were stabilized in 2% glutaraldehyde/PBS for 30’ and then rinsed in PBS followed by 0.05 M 
sodium acetate. After transfer to new vials, sections were silver-enhanced for 7’ using HQ silver 
enhancement kit (Nanoprobes 2012), rinsed with 0.05 M sodium acetate, and moved to 
phosphate buffer, pH 6.8. Sections for electron microscopy were then post-fixed 45’ in 0.5% 
osmium tetroxide in phosphate buffer, pH 6.8, rinsed, and placed in 0.1 M maleate buffer, pH 6, 
followed by 45’ in 1% uranyl acetate/MB. Sections were dehydrated through a graded ethanol 
series ending with 2 changes of 100% ethanol. Resin infiltration was 30’ in 1:1 ethanol/resin, 30’ 
1:3 ethanol/resin, then 2 changes in pure resin (Low Viscosity embedding kit—from Dr. Spurr, 
Electron Microscopy Sciences 14300). Infiltrated sections were sandwiched between 2 strips of 
ACLAR film (between 2 glass slides for support) and polymerized for 36-48 hours in an oven. 
56 
 
Small (1x1mm) areas of interest from neocortex were cut out and glued onto a support block. 
The tissue was trimmed and sectioned (50-60 nm) (Leica Ultracut R) and sections collected on 
300 mesh nickel or copper grids. Tissue sections were then counterstained with uranyl acetate 
followed by Sato’s lead and examined with a Tecnai 12 electron microscope.  
Immunoprecipitation and pull-down assays 
 
For coimmunoprecipitation of neurocan with NCAM140, NCAM mutants, or EphA3, 
HEK293T cells (cultured in DMEM, 10% fetal bovine serum) were transfected with EphA3 or 
NCAM140 cDNA (in pcDNA3.1 vectors) using Lipofectamine 2000 (Invitrogen). Proteins from 
cell lysates (1 mg) in RIPA buffer (20 mM Tris pH 7.0, 0.15 M NaCl, 5 mM 
ethylenediaminetetraacetic acid (EDTA), 1 mM EGTA, 1% NP-40, 1% deoxycholate, 0.1% 
sodium dodecyl sulfate (SDS), 200 μM Na3VO4, 10 mM NaF, 1X protease inhibitor (Sigma)), 
and proteins were precipitated using antibodies against EphA3 (C-19, Santa-Cruz), or NCAM 
(H-300 Santa-Cruz), with Protein A/G agarose beads (Thermo-Fisher). Co-immunoprecipitation 
from brain was performed using 1 mg of lysate in RIPA buffer. In some experiments, brain 
extracts were treated for 1 hr with endo-N (40 U) on ice prior to immunoprecipitation to remove 
PSA.5 Protein complexes were separated by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE), immunoblotted using antibodies to versican, aggrecan/brevican, neurocan, EphA3, 
NCAM, or phosphotyrosine, and detected with HRP-conjugated secondary antibodies. Pulldown 
analyses were performed by incubating 1 μg of neurocan (human or mouse) with Fc protein (1 
μg) (control Fc, NCAM-EC-Fc, NCAM Ig1-3, NCAM Ig1-2, NCAM Ig2, NCAM Ig1, or ephrin-
A5-Fc) in TBS for 1 hr at 37°C. Protein A/G Sepharose beads were used to pull down Fc 
proteins for detection by immunoblotting. For detection of EphA3 autophosphorylation, 
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HEK293T cells were cotransfected with NCAM-140 and EphA3 cDNA. Transfected cells were 
pre-treated with neurocan (20 nM) for 30 min prior to 
treatment with preclustered ephrin-A5-Fc or control Fc for 10 min,9 then lysed in RIPA buffer. 
EphA3 was immunoprecipitated, and tyrosine phosphorylation was detected with anti-PY99.  
Competitive binding assay 
 
HEK293T cells were transfected with NCAM-140 and EphA3. Recombinant neurocan 
was treated with 0.1 U/microgram chABC (Sigma) at 37°C for 1.5 hr or incubated with no 
enzyme (as a control), followed by heat inactivation of enzyme at 100°C for 10 min. Efficacy of 
chABC treatment was assessed by immunoblotting. Cells were treated with neurocan (20 nM), 
chABC treated neurocan (20 nM), or no neurocan (control) for 30 min. Cells were lysed and 
NCAM immunoprecipitated, and bound EphA3 and neurocan were detected by immunoblotting.  
Immunostaining and co-localization analysis 
 
For cortical neuron cultures, embryonic day 0.5 (E0.5) was defined as the plug date and 
cortical neuron cultures prepared at E15.5. Dissociated cortical neurons from WT mice were 
plated onto poly-D-lysine- and laminin coated Lab-Tek II chamber slides (1.5× 105 cells/well) as 
described.10,11 At 10 DIV, cells were pretreated with or without neurocan (4 nM) and then 
stimulated with 1 μg/mL preclustered Fc or ephrin-A5-Fc for 30 min. Cells were fixed in 4% 
paraformaldehyde and blocked/permeabilized in 0.5% TritonX-100/PBS with 10% horse serum. 
Slides were incubated in primary antibodies against NCAM, EphA3, and GABA overnight at 
4°C. Secondary antibodies (Alexa 405, Alexa 555, Alexa 647) were added for 1 hr and mounted 
using SlowFade (Life Technologies). Confocal images were obtained with Zeiss LSM700 and 
LSM710 microscopes using a Plan-Apochromat 63X 1.4 numerical aperture objective with 2X 
optical zoom using Zeiss Zen software. Only GABA-positive cells were imaged for analysis. Co-
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localization of NCAM and EphA3 was analyzed using the ImageJ plugins Colocalization_Test 
and Colocalization Threshold as described previously.12 Co-localization was expressed as R-
Total (the Pearson correlation coefficient, which varies between -1 and 1). Values were 
calculated for pixels above a threshold level determined by the regression algorithm contained in 
the “Colocalization Threshold” macro. For each condition, an average from measurements of at 
least 30 images was reported.  
Growth cone collapse assay 
 
Dissociated cortical neuron cultures were generated from WT mice as described above. 
At 10 DIV, cells were pre-treated with or without neurocan (4 nM) and then with preclustered 
ephrin-A5-Fc or human Fc (1 μg/mL) for 30 min, fixed, and growth cones visualized by 
immunofluorescence staining of GABA.5,12 Growth cones were scored as collapsed by bullet-
shaped morphology or noncollapsed by spread morphology by an observer blinded to treatment, 
and the percentage of collapsed growth cones of GABA-positive neurons was compared (10 





Degradation of PNN GAG chains reduces perisomatic synapse density in cortical slices 
 
To directly test the importance of PNN molecules in regulation of perisomatic 
GABAergic synapse density in the PFC, organotypic slice cultures were prepared from 
Parvalbumin-Cre;Ai9 (Lox-STOP-Lox tdTomato) mice, in which parvalbumin-positive 
interneurons express tdTomato throughout the soma and neuronal processes as a reporter of Cre-
dependent recombination.1,2 Interneurons in the PFC in these slice cultures form characteristic 
axon arbors and perisomatic boutons over 14 days in vitro (DIV)5 with a time course analogous 
to that observed in vivo.11 We focused on the anterior cingulate region of the PFC (layers 2,3), 
because it is a region where synaptic plasticity is pronounced and intra- and subcortical inputs 
are maximal.13,14 Wisteria Floribunda agglutinin (WFA) is a lectin that binds to residues found 
within PNN GAG chains.15 WFA labeling of PNNs in layers 2,3 of the anterior cingulate at 14 
DIV showed characteristic PNNs around populations of NeuN-positive neuronal soma, as well as 
tdTomato-labeled interneurons (Fig. 11A). 
To determine if GAG-modified PNNs restrained postnatal remodeling of perisomatic 
basket cell synapses, slice cultures (DIV12) were treated with a control enzyme (penicillinase) or 
the bacterial enzyme chondroitinase ABC (chABC) for 2 hours, followed by removal of enzyme 
and further incubation until fixation at DIV14 (equivalent postnatal day 19). Penicillinase is a 
bacterial-derived enzyme that is used as a non-relevant control for comparison to chABC.16 
chABC treatment was sufficient to remove PNNs as indicated by a loss of WFA staining in the 
chABC treated slices (Fig. 11B). Treatment with chABC significantly decreased the mean 
number of perisomatic puncta per soma in comparison to control penicillinase, implicating PNN 
proteins as a stabilizing factor for perisomatic synapses (Fig. 11C,D). Neurocan 
coimmunoprecipitated with NCAM in brain lysates (Fig. 11E), and previous work indicates that 
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purified NCAM and neurocan can associate in a partially GAG-dependent manner in vitro.17 
Chondroitinase ABC will target the GAG chains of neurocan and other CSPGs in PNNs. 
However, NCAM did not bind other CSPG proteins (versican, aggrecan, brevican), as shown by 
lack of co-immunoprecipitation from brain lysates (Fig. 11E). Although NCAM can bind the 
CSPG phosphacan, this depends on the core protein rather than GAG chains.18 
Although our chABC results in organotypic slices suggested that PNN components may 
regulate perisomatic synapses, no specific target of chABC in this process was identified. We 
hypothesized that neurocan may regulate perisomatic synapses based on its binding to NCAM. 
However, chABC treatment has also been shown to reduce tenascin-R,19 a PNN glycoprotein 
that contributes to formation and activity of perisomatic GABAergic interneurons in the CA1 
area of the hippocampus.20-23 Thus, we wanted to identify whether neurocan and/or tenascin-R 
were involved in setting the number of perisomatic GABAergic synapses in organotypic slices. 
To assess the role of these proteins in regulation of perisomatic synapses, we performed a rescue 
experiment in which organotypic slices were treated with control penicillinase or chABC (DIV 
10, 2 hours) followed by removal of enzyme and addition of no protein (untreated), neurocan, or 
tenascin-R. Rescue with recombinant neurocan but not tenascin-R prevented the decrease of 
perisomatic synapses previously observed after chABC treatment (Fig. 11F). However, further 
testing of the recombinant tenascin-R protein for the presence of HNK-1 carbohydrate 
modification indicated that the protein lacked detectable HNK-1 (Fig. 11G). HNK-1 
modification has been shown to be required for the synaptogenic effects of tenascin-R.20-23 The 
rescue experiment with recombinant neurocan indicates that neurocan but not tenascin-R lacking 




Figure 11: GAG-modified neurocan blocks chABC-induced decrease of perisomatic synaptic puncta in organotypic 
brain slices. (A) Immunostaining of neuronal soma (NeuN), a parvalbumin-positive interneuron (tdTomato), and a 
perineuronal net (WFA) in DIV14 organotypic brain slice culture. Scale bar=10 μm. (B) WFA labeling of 
perineuronal nets in control penicillinase and chABC-treated brain slices. Scale bar=30 μm. (C) Representative 
image of perisomatic synapses (tdTomato) in control penicillinase or chABC-treated slice cultures. Representative 
perisomatic puncta around a single soma are indicated with arrowheads. Scale bar= 10 μm. (D) Quantification of the 
mean number of perisomatic synaptic puncta per soma (n=30 soma/condition, 3 animals per condition, t-test, * 
p<0.05). (E) NCAM was immunoprecipitated from brain lysates, followed by immunoblotting with antibodies 
against neurocan, versican, or aggrecan/brevican (using an antibody raised against shared epitope). (F) Slices were 
treated with control penicillinase or chABC as in (C) followed by rescue with neurocan or tenascin-R. 
Quantification of the mean number of perisomatic synapses per soma 30 was performed (>90 soma per mouse per 
condition, n=3 mice, two-way ANOVA with Bonferonni post-hoc testing, * p<0.05). 
 
Expression of Neurocan and NCAM in the postnatally developing PFC 
 
The temporal and spatial expression of neurocan in the neocortex could affect its function 
in specific cell types or brain circuits. Neurocan was found to be prominently expressed in mouse 
brain at birth (postnatal day zero, P0), increased at early postnatal and adolescent stages (P10-
P21), and decreased at adulthood (P60) (Fig. 12A), similar to previous results in rat brain.24 
Neurocan was observed as a diffuse protein (130–250 kDa) on immunoblots due to GAG chain 
62 
 
modification. NCAM exhibited a similar developmental pattern of expression as neurocan and 
displayed regulated changes in polysialylation. NCAM was evident at P0-P21 as a high 
molecular weight (180–250 kDa) diffuse species that was recognized by PSA-specific antibodies 
(Fig. 12A). In young adults at P60 NCAM resolved into non-PSA NCAM isoforms of 180- and 
140-kDa, which differ only in the length of their cytoplasmic domains25 (Fig. 12A). 
The cellular localization of neurocan in the PFC was next evaluated by 
immunofluorescence staining in Parvalbumin-Cre;Ai9 reporter mice at P28 (immature) and P60 
(adult) (Fig. 12B). In the PFC of these mice, perisomatic puncta of TdTomato-positive basket 
cells co-localized with GAD65, a presynaptic marker enriched in GABAergic nerve terminals 
(Fig. 12B). Neurocan was abundant and diffusely localized throughout PFC laminae at P28, and 
decreased by P60 (Fig. 12C). Somata of many tdTomato-positive interneurons were distinctly 
outlined by neurocan immunofluorescence (9% and 17% at P28 and P60, respectively) (Fig. 
12C). Neurocan localization around pyramidal cells was validated by double immunostaining 
with the nuclear transcription factor MATH-2, which is specific for pyramidal neurons (Fig. 
12D).26 Neurocan staining was observed within approximately 1 μm of 81% of tdTomato-
positive perisomatic puncta around MATH-2-expressing pyramidal cells (Fig. 12D) (n = 3 mice, 
150 tdTomato puncta, SEM = 6%). Neurocan localization in the PFC (P18) was further probed at 
the electron microscope level by immunogold labeling. Neurocan labeling was observed at 
discrete sites along the somal membrane as well as in the extracellular space adjacent to soma 
(arrows, Fig. 12E). Neurocan labeling was sometimes seen at the somal membrane in proximity 
to synaptic vesicle-containing axon terminals (AT, open arrowhead; Fig. 12F), but was rarely 
seen within the cytoplasm. To verify the specificity of the neurocan antibody, COS7 cells were 
transfected to express neurocan fused to alkaline phosphatase (Neurocan-AP), or alkaline 
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phosphatase (AP) alone. Fixed cells were subjected to indirect immunoperoxidase staining with 
or without neurocan antibodies (Fig. 12G). Only cells expressing Neurocan-AP were positive for 
labeling. The AP transfected cells and control lacking primary antibody showed no signal, 
indicating specificity of the antibody. To assess the spatial relationship of neurocan and NCAM 
in both pyramidal neurons and inhibitory GABAergic interneurons, cortical neuron cultures 
(14DIV) were stained with antibodies against GABA, NCAM, and neurocan (Fig. 12H). Results 
indicated that both GABA-positive interneurons and GABA-negative neurons express NCAM 
and neurocan at neuronal soma (Fig. 12H). Together, these results showed that neurocan was 
preferentially localized in postnatally developing PFC near neuronal soma membranes and was 
present around both excitatory and inhibitory neurons. 
NCAM polysialylation inhibits binding to Neurocan 
 
Polysialylation of NCAM is required for ephrinA-induced repellent responses of 
GABAergic interneurons.5 To determine whether neurocan binds differentially to polysialylated 
NCAM or unmodified NCAM isoforms, NCAM and neurocan association was analyzed by co-
immunoprecipitation from brain lysates at P8, when NCAM is heavily polysialylated, and at P34, 
when only a small portion of NCAM is PSA-modified (Fig. 13A). Neurocan preferentially 
immunoprecipitated with non-PSA NCAM at P34 compared to PSA-NCAM at P8 (Fig. 13A,B). 
To determine if PSA removal increased NCAM/neurocan binding, P8 brain lysates were treated 
with or without endoneuraminidase N (EndoN) to remove PSA, followed by 
immunoprecipitation of NCAM. EndoN treatment was effective at decreasing NCAM 
polysialylation, and significantly increased neurocan binding to non-PSA NCAM-180 and 
NCAM-140 (Fig. 13C,D). These results support the conclusion that neurocan preferentially binds 




Figure 12: Expression of neurocan and NCAM in postnatal and adult brain. (A) Immunoblot of total brain extracts 
for neurocan, NCAM, PSA-NCAM, and GAPDH (loading control). (B) Co-localization of tdTomato puncta (red) 
with the presynaptic marker GAD65 (green) around a neuronal soma (blue). Scale bar=5 μm. (C) 
Immunofluorescent staining of neurocan (green) around PV+ tdTomato-labeled interneurons (red) in mouse frontal 
cortex at P28 and P60. Scale bar=50 μm. (D) Confocal images of neurocan (green) around perisomatic synaptic 
puncta (red) onto MATH-2 expressing pyramidal neurons (blue nucleus, outlined with white border). A magnified 
inset is indicated with a white box. Scale bars=2.5 μm. (E) Electron micrograph of immunogold labeling for 
neurocan along the membrane of a neuronal soma (black arrows point to examples). Scale bar=1 μm. (F) Electron 
micrograph of an inhibitory axon terminal onto a neuronal soma. Neurocan immunogold labeling is indicated with 
black arrows, and the axon terminal (AT) is labeled with a white arrowhead. Cytoplasm and nucleus of the soma are 
identified with text. Scale bar=1 μm. (G) Verification of neurocan antibody specificity by immunostaining of COS7 
cells transfected with Neurocan-AP (+ control) or AP (- control), and a no primary antibody control. Scale bar=50 
μm.(H) Immunofluorescent localization of NCAM and neurocan in GABA+ and GABA- cortical neuron cultures. 
Confocal images of GABA (green), NCAM (blue), and neurocan (red) in cortical neuron cultures. White arrow 
indicates a GABAnegative neuron positive for NCAM and neurocan, and the green neuron represents a GABAergic 




Figure 13: PSA inhibits binding of NCAM to neurocan. (A) Co-immunoprecipitation of neurocan and NCAM from 
P8 or P34 brain extracts immunoblotted for neurocan, NCAM, and PSA-NCAM. (B) Densitometry of (A). Graph 
indicates the ratio of bound neurocan to immunoprecipitated NCAM using black bars and ratio of PSA-NCAM to 
total NCAM in brain lysate (white bars) (n=3, t-test, * p<0.05). (C) Coimmunoprecipitation of neurocan and NCAM 
from untreated or EndoN-treated brain extracts immunoblotted for neurocan, NCAM, and PSA-NCAM. (D) 
Densitometry of (C). Graph indicates the ratio of bound neurocan to immunoprecipitated NCAM (black bars) and 
ratio of PSA-NCAM to total NCAM in brain lysate (white bars) (n=3, t-test, * p<0.05). 
 
Neurocan binds to the Ig2 domain of NCAM 
 
NCAM contains a heparin sulfate proteoglycan (HSPG) binding site in its Ig2 domain,12 
and residues within this proteoglycan binding domain (R156 and K162) are required for EphA3 
binding.27 Because the CSPG neurocan and HSPGs are extensively modified by GAG chain 
addition, it was hypothesized that neurocan engages the NCAM extracellular region (NCAM-
EC) within the Ig2 proteoglycan binding domain. The neurocan binding site on NCAM was 
identified using assays in which Fc fusion proteins consisting of human NCAM Ig1-5/FN1-2 
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(full-length NCAM-EC), Ig1-3, Ig1-2, Ig2, and Ig1 (or Fc alone as a control) were incubated 
with recombinant human neurocan, and then pulled down with Protein A/G-Sepharose beads. 
Results showed that neurocan bound most effectively to full-length NCAM-EC and NCAM Ig2 
(Fig. 14A,B). Neurocan bound to a lesser extent to NCAM truncation fragments Ig1-3, Ig 1-2, 
and Ig1 (50%, 33%, and 23% compared to NCAM-EC-Fc binding, respectively) (Fig. 14A,B). 
Quantification of binding showed that neurocan binding to NCAM Ig2-Fc was greater than to 
NCAM-EC (129% compared to amount of neurocan bound to NCAM-EC-Fc) (Fig. 14A,B). 
Apart from Ig1-Fc, all other constructs tested contained the Ig2 domain but bound with varying 
affinities to neurocan. Structural studies suggest that NCAM forms dimers through cis 
interactions between its Ig1 and Ig2 domains28 and also trans interactions involving Ig3. The 
presence or absence of various Ig domains may influence the ability of NCAM to dimerize in 
solution, affecting accessibility of the Ig2 binding site of neurocan and potentially resulting in 
different affinities for neurocan binding. As the NCAM Ig2-Fc fragment is free from dimer-
induced steric hindrance by Ig1 or Ig3, it may be more accessible for neurocan binding, which is 
consistent with the binding results. 
Neurocan contains a carboxyl terminal sushi domain, a structure known to mediate 
protein-protein interactions. NCAM binds EphA3 at its cysteine-rich-domain (CRD), which also 
contains a sushi domain.27 The Ig family member, L1-CAM, interacts with the sushi domain of 
neurocan.29 Thus, it was hypothesized that the sushi domain of neurocan might be involved in 
NCAM/neurocan binding. The contribution of the neurocan sushi domain to NCAM binding was 
tested using recombinant human neurocan (full-length protein) or mouse neurocan Glu23-637 (a 
truncation lacking the sushi domain). These recombinant neurocan proteins were incubated with 
human NCAM-EC-Fc, and the amount of bound neurocan was assessed after Fc-pulldown. Both 
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mouse and human neurocan bound efficiently to NCAM-EC-Fc. Binding of mouse neurocan 
lacking the sushi domain was somewhat decreased compared to full-length neurocan (93% 
relative to human neurocan level bound to NCAM), but this difference was not statistically 
significant (p = 0.23, t-test) (Fig. 14C). 
A complementary charged interface between the extracellular NCAM Ig2 domain and the 
EphA3 CRD mediates the binding and clustering of NCAM and EphA3 in the neuronal 
membrane. Amino acids R156 and K162 in the NCAM Ig2 domain were identified by molecular 
modeling and determined to be important residues for NCAM binding to EphA3.27 These 
residues are also part of a domain required for NCAM binding to heparin sulfate proteoglycans 
(HSPGs).28 In contrast, another Ig2 residue (NCAM R192) is not within the EphA3 binding 
site.27 To assess the contribution of residues in NCAM Ig2 to neurocan binding, lysates of 
HEK293T cells expressing wild type (WT) NCAM or NCAM mutants (R156E, K162D, and 
R192E) were incubated with full-length neurocan, and the amount of neurocan co-
immunoprecipitating with NCAM was analyzed by immunoblotting. Neurocan co-
immunoprecipitated with WT NCAM and NCAM R192E, but bound to a much lesser extent 
with NCAM R156E and K162D mutants (32% and 41% of WT) (Fig. 14D,E, p < 0.05). These 
results indicate that neurocan binding to NCAM Ig2 involves residues involved in EphA3 
association and HSPG binding. 
Neurocan GAG chains mediate NCAM binding and disrupt the NCAM/EphA3 interaction 
 
The shared NCAM binding site of neurocan and EphA3 led us to the hypothesis that 
competitive binding may occur between these proteins. To assess the ability of neurocan to 
disrupt NCAM/EphA3 binding and to test the importance of GAG chains in this process, a cell-




Figure 14: Neurocan binds the Ig2 domain of NCAM, decreasing EphA3 binding. (A) Fc pulldowns of the NCAM 
extracellular domain (NCAM-EC), truncation mutants of NCAM, or control Fc and recombinant neurocan. (B) 
Densitometry of (A) indicating the level of neurocan bound (relative to positive control NCAM-EC-Fc bound 
neurocan) for each construct (* p<0.05 compared to NCAM-EC-Fc) (C) Fc-pulldowns of NCAM-EC-Fc or control 
Fc with mouse neurocan (lacking sushi domain) and full-length human neurocan. (D) Co-immunoprecipitation of 
WT NCAM-140 or mutants of NCAM and neurocan from transfected HEK293T cells. (E) Densitometry of (D). The 
amount of coimmunoprecipitated neurocan for each NCAM IP was normalized to control WT NCAM bound 
neurocan (n=3, t-test, * p<0.05). (F) Immunoblot of untreated or chABC-treated neurocan protein probed for 
neurocan or C-4-S. (G) Co-immunoprecipitation of NCAM-140 and EphA3 from transfected HEK293 cells treated 
with no neurocan (control), neurocan, or chABC-treated neurocan. (H) Densitometry of (G). The amount of co32 
immunoprecipitated EphA3 for each NCAM IP was normalized to control NCAM-bound EphA3 (n=3, t-test, * 
p<0.05). 
 
neurocan with chABC followed by heat inactivation of enzyme. The efficiency of GAG removal 
was confirmed by a loss of high molecular weight GAG-modified neurocan by SDS-PAGE (Fig. 
14F).  
Further confirmation of chABC efficacy was obtained by immunoblotting for 
chondroitin-4-sulfate (C-4-S) stubs which are generated after chABC treatment. C-4-S signal 
was observed after chABC treatment but not in control sample processed without enzyme, 
indicating that chABC treatment was effective (Fig. 14F). HEK293T cells expressing non-PSA 
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NCAM-140 and EphA3 were treated with neurocan, chABC-pretreated neurocan, or left 
untreated prior to lysis. NCAM-140 was immunoprecipitated, and the amounts of bound EphA3 
and neurocan were analyzed by immunoblotting. EphA3 binding was significantly decreased to a 
level of 25% of control in neurocan-treated cells (p < 0.05), but chABC-treated neurocan did not 
significantly alter EphA3 binding (p > 0.05) (Fig. 14G,H). Furthermore, after chABC treatment, 
69% less neurocan was bound to non-PSA NCAM-140 compared to control neurocan (Fig. 14G, 
p < 0.05). These results indicated that neurocan decreased binding of EphA3 to non-PSA NCAM, 
and that neurocan/NCAM binding required intact GAG chains of neurocan. 
Neurocan inhibits Ephrin-A5-induced clustering/activation of NCAM and EphA3 in 
cultured cortical interneurons 
 
The activation of Eph receptor signaling is initiated by ephrin-induced receptor 
oligomerization in the plasma membrane.30 Mechanistically, NCAM promotes ephrin-A-induced 
repulsion in GABAergic neurons by stimulating EphA3 receptor clustering, tyrosine kinase 
activation, and signaling through the small GTPase RhoA.27 NCAM has been shown to co-
cluster with EphA3 and to potentiate oligomerization in processes of GABAergic interneurons in 
cortical cultures.27 The effect of neurocan on ephrin-A5-induced clustering of endogenous 
NCAM and EphA3 was assessed in mouse cortical cultures using this assay.27 Neuronal cultures 
(14 DIV) were incubated with or without recombinant neurocan (4 nM, 30 minutes) before 
stimulation with control Fc or ephrin-A5-Fc for 30 minutes. Immunostaining of NCAM, EphA3, 
and GABA (to identify interneurons) was performed after cell fixation. Co-clustering of NCAM 
and EphA3 was analyzed in confocal images in which only GABA-labeled regions of interest 
(ROIs) were selected using ImageJ co-localization software. Results of the analysis yielded 
Pearson’s Correlation Coefficients (R-Total), ranging from −1 (no correlation) to 1 (absolute 




Figure 15: Neurocan impairs ephrin-A5-mediated clustering of NCAM and EphA3 in cortical interneurons in 
culture. (A) Cortical neuron cultures were pretreated with no neurocan (control) or neurocan followed by 
preclustered Fc or ephrin-A5-Fc, and localization of endogenous NCAM (green) and EphA3 (red) was assessed in 
axons of GABA immunopositive axons by confocal microscopy. Scale bars = 5 μM. (B) Pearson’s Correlation 
Coefficients (R-Total) were generated for each condition using ImageJ colocalization software (n=3, two-way 
ANOVA with Bonferonni post-hoc testing, * p<0.05). 
 
EphA3 as seen in merged images and a 4-fold increase in R-Total (Fig. 15A,B). In contrast, 
ephrin-A5-induced co-localization of NCAM and EphA3 in neurocan-treated cells was 
significantly reduced (Fig. 15A,B). These findings show that neurocan can block NCAM/EphA3 
co-clustering on GABAergic neuronal processes, in accord with its ability to perturb binding. 
Ephrin-A-induced clustering of EphA receptors induces autophosphorylation of tyrosine 
residues in the receptor cytoplasmic domain31,32 leading to downstream signaling. To evaluate 
the consequences of neurocan on EphA3 kinase activation, EphA3 autophosphorylation was 
assessed in HEK293T cells co-expressing NCAM-140 and EphA3. Cells were treated with or 
without neurocan (20 nM, 30 minutes), then stimulated with control Fc or ephrin-A5-Fc. EphA3 
was immunoprecipitated and immunoblotted with phosphotyrosine antibody (PY99), followed 
by stripping and reprobing for EphA3 protein. The ratio of phospho-EphA3 to total EphA3 was 
quantified by densitometry and compared for significant differences. In control cultures treated 
with ephrin-A5-Fc, EphA3 phosphorylation was strongly increased in comparison to Fc treated 
cells (Fig. 16A,B). In neurocan-treated cells, ephrin-A5-induced EphA3 autophosphorylation 




Figure 16: Neurocan decreases ephrin-A5-induced EphA3 autophosphorylation. (A) HEK293T cells transfected 
with NCAM and EphA3 were treated with preclustered control Fc or ephrin-A5-Fc, and EphA3 was 
immunoprecipitated. EphA3 autophosphorylation was assessed by immunoblotting with a phosphotyrosine antibody 
(PY99). Total levels of immunoprecipitated EphA3 were assessed by reprobing with EphA3 antibody. (B) 
Densitometry of (A). Graph indicates the ratio of phosphotyrosine to EphA3 values for each condition (n=3, * 
p<0.05). (C) Fc-pulldowns of control Fc, NCAM-EC-Fc, and ephrin-A5-Fc with recombinant neurocan. Level of 
neurocan bound (relative to positive control NCAM-EC-Fc bound neurocan) is indicated as a percentage under each 
lane. (D) Co-immunoprecipitation of NCAM (positive control) or EphA3 with neurocan from transfected HEK293T 
cells. Level of neurocan bound (relative to positive control NCAM-EC-Fc bound neurocan) is indicated as a 
percentage under each lane. 
 
 
Figure 17: Neurocan inhibits ephrin-A5-induced growth cone collapse in GABAergic interneurons. (A) 
Representative spread and collapsed growth cones of GABA33 immunostained interneurons in cortical neuron 
cultures. Scale bar = 5 μM. (B) The percentage of collapsed growth cones was determined for each condition (300 




NCAM/EphA3/ephrin-A5 signaling complex was also assessed. In pull down assays, purified 
recombinant neurocan bound to NCAM-EC-Fc but did not bind ephrin-A5-Fc (relative level of 
neurocan bound to EphrinA5-Fc was 0.6% of neurocan bound to NCAM-EC-Fc, n = 3, p < 0.05) 
(Fig. 16C). Results of co-immunoprecipitation from HEK293T cells expressing NCAM140 or 
EphA3 indicated that neurocan bound to NCAM but not to EphA3 (relative level of neurocan 
bound to EphA3 was 2.7% of neurocan bound to NCAM, n = 3, p < 0.05) (Fig. 16D). Together, 
these results indicated that neurocan engages NCAM at the same extracellular motif required for 
EphA3 binding, inhibiting ephrin-A5-induced receptor clustering and EphA3 receptor activation. 
Neurocan perturbs Ephrin-A5-induced growth cone collapse of GABAergic interneurons 
 
Growth cone collapse in cultured neuronal cells is widely used for characterization of 
ephrin/Eph repellent responses.33-35 Growth cone collapse of wild type (WT) versus NCAM null 
GABAergic neurons in culture closely correlates with perisomatic synapse densities in WT and 
NCAM null mice.5,27 NCAM is required for ephrin-A5-mediated growth cone collapse of 
GABAergic interneurons in vitro,5,27 but neurocan has not been tested for inhibition of this 
repellent response. To assess the effect of neurocan on ephrin-A5-induced growth cone collapse, 
mouse cortical neuron cultures (14 DIV) were treated with or without neurocan (4 nM, 30 min). 
Neurons were then stimulated with pre-clustered Fc or ephrin-A5-Fc for 30 minutes, and cultures 
were fixed and immunostained for GABA to identify interneurons. Neuronal growth cones of 
GABA-positive interneurons were scored as collapsed (bullet-shaped) or not collapsed (fan-
shaped) based on morphology as described.5,27 Ephrin-A5-Fc induced robust growth cone 
collapse (~55%) in untreated GABA-positive neurons, and this response was fully blocked in 
cells treated with neurocan (Fig. 17A,B). A fraction of neuronal cells were refractive to ephrin-
A5-induced collapse, and may represent a subpopulation that does not express ephrin-A5 
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receptors, NCAM, and/or required signaling effectors. These results demonstrate that neurocan is 
capable of blocking ephrin-A5-induced repellent signaling in cortical interneurons. In 
combination with the effect of chABC on interneuron perisomatic synapse density in slice 
cultures, this functional assay supports a role for neurocan in inhibitory synapse maturation in 






Here we identify a previously unknown role for the PNN protein neurocan in disrupting 
NCAM interaction with EphA3 to terminate repellent responses and limit the number of 
perisomatic inhibitory synapses made by basket interneurons onto pyramidal neurons in the 
mouse PFC. Targeting GAG chains of PNN proteins using the enzyme chABC decreased 
perisomatic synapse numbers in PFC layers 2,3 of organotypic brain slices, highlighting a 
previously unknown role for PNNs in regulating inhibitory synapse density of PV+ interneurons 
in the PFC. Furthermore, neurocan was able to rescue the observed effects of chABC treatment. 
The present study further shows that neurocan perturbs NCAM/EphA3 receptor clustering by 
binding to the same critical determinants in the NCAM Ig2 domain that are required for binding 
to EphA3. As a consequence, neurocan inhibits EphA3 kinase activation and impairs ephrin-A5-
induced growth cone collapse in GABAergic neurons. During postnatal stages of developmental 
synapse remodeling in the PFC, neurocan accumulated in the extracellular space and was closely 
associated with excitatory and inhibitory neurons. Neurocan was observed in close apposition 
with inhibitory perisomatic terminals by light and electron microscopy, but it did not colocalize 
within synapses. 
Removal of the GAG chains of PNN proteins resulted in a decrease in GABAergic 
perisomatic synapse density in cortical organotypic slice cultures. The current binding studies 
and previous work suggest that this effect is unlikely to derive from an effect on NCAM binding 
to other PNN proteins, although experiments knocking down individual PNN components could 
be informative. A recent study showed that brevican promotes maturation of excitatory synapses 
contacting the soma of PV+ interneurons,36 thus different PNN components may regulate 
perisomatic synapses in distinct neuronal cell types. 
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Polysialylation of NCAM is associated with synaptic plasticity and remodeling of 
perisomatic synapses.5,37 Neurocan interacted robustly with non-PSA NCAM isoforms but not 
with PSA-NCAM. The finding that PSA inhibited NCAM binding to neurocan suggests that 
polysialylation is a critical modification that allows remodeling during early development, which 
is later halted by the loss of PSA that occurs during maturation to terminate developmental 
plasticity. Developmental regulation of NCAM polysialylation may mediate the transition 
between remodeling of excess basket cell axon terminals and their stabilization at perisomatic 
synapses by modulating interaction with neurocan. Domain truncation analysis of NCAM 
mapped the key interaction site to the NCAM Ig2 domain. While the sushi domain of neurocan is 
essential for binding to L1,29 this domain was not required for binding to NCAM. An interface 
involving complementary charged residues in the interacting domains of NCAM (Ig2) and 
EphA3 (CRD)27 was found to mediate NCAM binding to neurocan. Basic residues in NCAM Ig2 
(R156 and K162) were essential for interaction of NCAM with both neurocan and EphA3. These 
residues are positioned within the heparin-binding site of NCAM, which is essential for 
interaction of NCAM with extracellular matrix HSPGs.38 Neurocan binding to NCAM at the 
heparin binding site (which also has affinity for CSPGs)39 may promote cell-matrix adhesion as a 
necessary step for synapse stabilization at pyramidal cell soma. This interpretation is compatible 
with the decreased numbers of perisomatic synapses observed after chABC treatment. 
Pulldown experiments with purified proteins demonstrated direct binding of NCAM to 
neurocan, but not to ephrin-A5 or EphA3. Neurocan interaction with NCAM was strongly 
dependent on GAG chains, but even the core protein of neurocan retained some binding affinity 
for NCAM. Neurocan blocked co-clustering of NCAM and EphA3 receptors on processes of 
cortical interneurons stimulated with the ligand ephrin-A5, suggesting that neurocan binding to 
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NCAM in the plasma membrane displaces EphA3. Neurocan treatment also inhibited ephrin-
dependent EphA3 autophosphorylation. As clustering of EphA receptors is essential for kinase 
activation and downstream signaling at localized sites in the neuronal membrane,30 the finding 
that neurocan can destabilize EphA3 clusters reveals an additional level of regulation in 
modulating ephrin-dependent repellent activity. 
In a functional assay of ephrin-dependent signaling, neurocan significantly perturbed 
ephrin-A5-dependent growth cone collapse. Because NCAM is required for ephrin-A5-
dependent growth cone collapse of cortical interneurons,3,27 results are consistent with the 
interpretation that neurocan/NCAM interactions impair EphA3 clustering and downstream 
signaling to inhibit ephrin-A-induced axonal repellent responses. Although growth cone collapse 
in vitro correlates with inhibitory synapse densities observed in vivo,5 the culture assay does not 
distinguish ephrin-A5-induced growth cone repulsion from elimination of nascent synaptic 
contacts. To address this question, live imaging of perisomatic synapse formation and 
elimination in vivo could be informative. 
This study delineates a novel molecular mechanism in which neurocan disrupts 
NCAM/EphA3 receptor clustering, EphA3 tyrosine kinase activation, and repellent responses of 
axon terminals in interneurons in the developing PFC. Results support a model (Fig. 18) in 
which PSA-NCAM enables NCAM/EphA3 clustering and signaling to eliminate excess 
presynaptic contacts of PV+ interneurons with pyramidal cell soma in early postnatal 
development. Upon maturation, neurocan in the forming PNNs binds to accumulating non-PSA 
NCAM, inhibiting ephrinA5/EphA3-mediated repellent responses and stabilizing inhibitory 
perisomatic synapses (Fig. 8). NCAM and EphA3 are both prominently involved in development 
of the nervous system, and neurocan is a potential risk factor in schizophrenia40 and bipolar 
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disorder41. Therefore, understanding how the PNN component neurocan influences the function 
of NCAM and EphA3 is relevant to both normal development and disease states. 
 
 
Figure 18: Model of inhibition of NCAM/EphA3 clustering and activation by neurocan. During postnatal 
remodeling of transient perisomatic synapses made by PV+ interneurons onto pyramidal cell soma, ephrin-A5 
dimers bind the ligand binding domains (LBD) of an EphA3 dimer. NCAM clusters the EphA3 receptors through 
binding of the NCAM Ig2 domain to the EphA3 CRD. EphA3 clustering activates tyrosine kinase signaling leading 
to synapse retraction. With further maturation, neurocan in PNNs engages the Ig2 domain of non-PSA NCAM, 
inhibiting EphA3 clustering and retraction of inhibitory perisomatic contacts. NCAM is shown in black, EphA3 is 
green, and ephrin-A5 is yellow. Neurocan core protein is depicted in purple with GAG chains in orange on a PNN 
scaffold (blue). P = phosphorylation. The illustration was created by modifying images purchased in the PPT 
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